Document:

<PAGE>

                                                                    Exhibit 10.6

                           EXCLUSIVE LICENSE AGREEMENT

                                     between

NOVO NORDISK A/S, Novo Alle, 2880 Bagsvaerd, Denmark - Danish company
identification number CVR 24 25 67 90 (hereinafter referred to as "NOVO
NORDISK")

                                       and

AMICUS THERAPEUTICS, Inc., 675 U.S. Highway One, North Brunswick, NJ 08902, USA
(hereinafter referred to as "AMICUS THERAPEUTICS").

Hereinafter individually referred to as "Party" and collectively as "Parties";

                                   WITNESSETH:

WHEREAS,   AMICUS THERAPEUTICS is involved in development of small molecule
           enzyme chaperones for treatment of genetic and metabolic diseases;

WHEREAS,   NOVO NORDISK is the owner of certain Intellectual Property Rights
           relating to glycogen phosphorylase inhibitors, its use and in
           particular patent rights relating to a specific glycogen
           phosphorylase inhibitor NN4201;

WHEREAS,   NOVO NORDISK wishes to license to AMICUS THERAPEUTICS such
           Intellectual Property Rights; and

WHEREAS,   AMICUS THERAPEUTICS wishes to acquire a license to such Intellectual
           Property Rights from NOVO NORDISK;

NOW, THEREFORE, the Parties agree as follows:

1.   BACKGROUND

1.1  As of the Effective Date and upon the terms and subject to the conditions
     of this Agreement, NOVO NORDISK agrees to grant to AMICUS THERAPEUTICS, and
     AMICUS THERAPEUTICS agrees to acquire from NOVO NORDISK, a license to the
     Intellectual Property Rights (as further defined in Article 2.1.9 below),
     free of any and all security interests, options or other third party rights
     (including but not limited to rights of pre-emption and royalties) of any
     nature what so ever.

2.   DEFINITIONS

2.1  For the purpose of this Agreement, the following terms shall have the
     following meanings in this Exclusive License Agreement and its appendices:

     2.1.1 "Affiliate" means any company, corporation, or other business entity
          which controls, is controlled by, or is under common control with, a
          Party hereto.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       1
<PAGE>

          "Control," including the terms "controlled by" or "under common
          control with," shall mean (a) in the case of corporate entities,
          direct or indirect ownership of stock or shares having the power to
          elect a majority of directors or similar body which governs the
          affairs of such corporate entity; and b) in the case of non-corporate
          entities, direct or indirect ownership of equity interest with the
          power to direct the management and policies of such non-corporate
          entities.

     2.1.2 "Agreement" shall mean this Exclusive License Agreement including its
          appendices.

     2.1.3 "Analogue" shall mean any chemical structure that is a structural
          homolog to, or derived from, the Compound and is covered by NOVO
          NORDISK Intellectual Property Rights.

     2.1.4 "Annual Net Sales" means the gross invoice price of the Licensed
          Product per year sold by AMICUS THERAPEUTICS, its Affiliates or
          sublicensees to independent Third Party customers in bona fide
          arms-length transactions, less the following deductions:

          (a)  trade, cash and/or quantity discounts actually taken;

          (b)  sales taxes, use taxes, tariffs, customs duties and value added
               or other taxes;

          (c)  Outbound transportation prepaid or allowed;

          (d)  refunds, rebates, allowances, credits or returns, including
               amounts repaid or credited by reason of rejections, return of
               goods or retroactive price reductions.

          For Annual Net Sales of a Licensed Product sold or supplied as a
          Combination, the Annual Net Sales of such a Combination in a country
          shall be determined as follows:

          A) by multiplying the Annual Net Sales of the Combination by the
          fraction A/(A+B), where A is the invoice price of the Licensed Product
          in that country if sold separately and B is the total invoice price of
          any other active component or components in the Combination in that
          country if sold separately; or If the Licensed Product and the other
          active component or components in the Combination are not sold
          separately, the Annual Net Sales, for purposes of determining
          royalties on the Combination, will be calculated by multiplying the
          Annual Net Sales of the Combination by the fraction determined by
          mutual agreement of the Parties, that reflects the relative
          contribution in value that the Licensed Product contained in the
          Combination makes to the total value of such Combination to the end
          user.; and

          B) if the Licensed Product contained in the Combination is not sold in
          that country in a vial, the Parties shall negotiate in good faith the
          value of the cartridge or prefilled device and/or other biologically
          active pharmaceutical(s) to be deducted from the Annual Net Sales of
          the Combination.

     2.1.5 "Combination" means A) where a Licensed Product is sold or supplied
          as a pharmaceutical product containing, in addition to the Licensed
          Product, one or more biologically active pharmaceuticals which are not
          a Licensed

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       2
<PAGE>

          Product, and/or B) where the Licensed Product is sold or supplied
          incorporated in a cartridge or prefilled device.

     2.1.6 "Compound" shall refer specifically to the compound identified as NNC
          42-1001 or NN4201 having the systematic name (2R, 3R,
          4R)-2-hydroxymethyl-pyrrolidine-3,4-diol. The IUPAC name for the
          tartaric salt of this compound is (2R, 3R,
          4R)-3,4-dihydroxy-2-hydroxymethyl)pyrrolidinum
          (2S,3S)-3-carboxy-2,3-dihydroxy-propanoate.

     2.1.7 "Effective Date" shall mean the date of the last signature to this
          Agreement.

     2.1.8 "Field" shall mean any and all human therapeutic or diagnostic
          indications.

     2.1.9 "Intellectual Property Rights" shall mean discoveries, know-how, data
          and technical information owned and controlled by NOVO NORDISK related
          to the NOVO NORDISK proprietary information, patents and patent
          applications delineated in Appendix A (and in respect of Patent
          Cooperation Treaty applications, European Patent Convention
          applications or applications under similar administrative
          international conventions, patent applications in the listed or
          designated countries), as well as any and all patents derived from
          these patents and patent applications, including selection patents,
          continuations, continuations-in-part, continued prosecutions
          applications, divisionals, reissues, re-examinations, renewals, or
          extensions, of the listed patent rights or any legal equivalent
          thereof which have been or may be filed in any country for the full
          term or terms for which the same may be granted. Extensions shall
          include: (a) extensions under U.S. Patent Term Restoration Act; (b)
          extensions under Japanese Patent Law; (c) Supplementary Protection
          Certifications (SPCs) according to Council Regulation (EEC) No 1768/92
          for members of the European Patent Convention and other countries in
          the European Economic Area, and (d) similar extensions under
          applicable law anywhere in the world.

     2.1.10 "Licensed Product(s)" shall mean any compound including but not
          limited to Compound, which is made, used, sold or offered for sale
          and/or imported in at least one country as a human therapeutic and
          that (a) is identified, discovered, made or developed, by AMICUS
          THERAPEUTICS for the benefit or on behalf of any Third Party, using a
          method covered by a Valid Claim of the Intellectual Property Rights,
          or (b) reasonably could not have been identified, discovered, made,
          used, developed, imported, offered for sale or been sold by AMICUS
          THERAPEUTICS but for the Intellectual Property Rights, or (c) is
          otherwise covered by a Valid Claim of the Intellectual Property Rights
          and would, in the absence of the License granted under this Agreement,
          infringe any Valid Claim. For the avoidance of doubt, Licensed Product
          includes compounds as described in the preceding sentence which are
          being made for and/or used in clinical trials in humans for the
          purpose of obtaining regulatory approval for use as an human
          therapeutic. Licensed Product also includes any Replacement Product(s)
          that may be developed under the Agreement.

     2.1.11 "NOVO NORDISK Data" as used herein, shall mean all NOVO NORDISK
          scientific and clinical/regulatory data relating to the use of
          Compound in humans.

     2.1.12 "Replacement Product" shall mean any Licensed Product which is a
          replacement for the Licensed Product or a potential Licensed Product.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       3
<PAGE>

     2.1.13 "Territory" shall mean all countries in the world.

     2.1.14 "Third Party", as used herein, shall mean all individuals or
          entities other than NOVO NORDISK and AMICUS THERAPEUTICS and any of
          their respective Affiliates and/ or sublicensees.

     2.1.15 "Valid Claim" shall mean a claim of any unexpired patent or patent
          application within Intellectual Property Rights so long as such claim
          shall not have been held invalid or unenforceable in a final decision
          rendered by tribunal of competent jurisdiction from which no appeal
          has been or can be taken.

3.   CONSIDERATIONS AND GRANT OF RIGHTS

3.1  NOVO NORDISK hereby grants to AMICUS THERAPEUTICS and its Affiliates an
     exclusive, worldwide, royalty-bearing license, with right to sublicense
     without restriction (provided that AMICUS THERAPEUTICS and its Affiliates
     remain responsible for the performance of their sublicensees), under the
     Intellectual Property Rights, to use, develop, promote, manufacture, have
     manufactured, market, register, package, distribute, sell, offer for sale,
     have sold, import, export and otherwise commercialize Licensed Products in
     the Field throughout the Territory (the "License"). NOVO NORDISK hereby
     also grants to AMICUS THERAPEUTICS the exclusive right and license to use
     the NOVO NORDISK Data in connection with regulatory filings with the U.S.
     Food and Drug Administration and other comparable international regulatory
     bodies for approval of the Licensed Products.

3.2  If NOVO NORDISK determines, after consultation with AMICUS THERAPEUTICS,
     that NOVO NORDISK controls or owns other Intellectual Property Rights as of
     the Effective Date, that are necessary for the development, use or
     manufacture of Licensed Products, then NOVO NORDISK shall to the extent
     legally possible include such other Intellectual Property Rights in the
     License granted under Article 3.1. If any such other Intellectual Property
     Rights are included in the License after the Effective Date, these shall be
     added to Appendix A together with the date for addition of them.

3.3  In consideration of the License granted hereunder to AMICUS THERAPEUTICS
     and its Affiliates, AMICUS THERAPEUTICS, its Affiliates or its sublicenses
     agree to pay to NOVO NORDISK the milestone payments and royalties set forth
     in this Article 3.3 and Article 3.4.

     a)   A total of [***] USD [***] to be paid in full no later than fifteen
          business days after the Effective Date into an account in the bank
          defined in Article 3.5.

     b)   A total of [***] USD [***] to be paid in full no later than fifteen
          business days after the IND filing in the US for each indication.

     c)   A total of [***] USD [***] to be paid in full no later than fifteen
          business days after initiation of a Phase III clinical trial (the date
          of the Investigator's meeting) in the US for each indication.

     d)   A total of [***] USD [***] to be paid in full no later than fifteen
          business days after filing of an NDA in the US for each indication.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       4
<PAGE>

     e)   A total of [***] USD [***] to be paid in full no later than fifteen
          business days after filing with EMEA for each indication.

     f)   A total of [***] USD [***] to be paid in full no later than fifteen
          business days after filing for regulatory approval in Japan for each
          indication.

     g)   A total of [***] USD [***] to be paid in full no later than fifteen
          business days after regulatory approval in the US for each indication.

     h)   A total of [***] USD [***] to be paid in full no later than fifteen
          business days after regulatory approval in EMEA for each indication.

     i)   A total of [***] USD [***] to be paid in full no later than fifteen
          business days after regulatory approval in Japan for each indication.

     The above milestone payments shall be payable once for the first Licensed
     Product achieving these milestones for an indication. AMICUS THERAPEUTICS
     shall also make milestone payments to NOVO NORDISK for each Replacement
     Product developed by AMICUS THERAPEUTICS and/or a sublicensee achieving
     milestones (d) through (i) for an indication, provided that each milestone
     payment amount shall be reduced by [***]. For the purposes of determining
     the satisfaction of these milestones, the category of diseases known as
     lysosomal storage diseases, and all classes of diseases within such
     category, shall be counted collectively as one indication (provided,
     however, that such disease is an orphan drug indication (US)), and all
     other human diseases shall each be counted individually as one indication.

3.4  Royalties will be payable by AMICUS THERAPEUTICS, its Affiliates or its
     sublicensees to NOVO NORDISK on a product to-by product and country by
     country basis until the last to expire of the NOVO NORDISK Intellectual
     Property Rights claiming the making, using, selling, offering to sell
     and/or import of such Licensed Product in such country. The Royalty rates
     shall be according to the following:

                           [table begins on next page]

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       5
<PAGE>

Table 1

<TABLE>
<CAPTION>
LICENSED PRODUCT DESCRIPTION                                             ANNUAL NET SALES                ROYALTY
----------------------------                               -------------------------------------------   -------
<S>                                                        <C>                                           <C>
Has Compound as an active component and the indication                 $25 million or less                  [***]%
is a lysosomal storage disease or other orphan drug (US)   > $25 million but less than or equal to $50      [***]%
indication:                                                                  million
                                                             > $50 million but less than or equal to        [***]%
                                                                           $100 million
                                                                          > $100 million                    [***]%

Has Compound as an active component and the indication                 $25 million or less                  [***]%
is other than a lysosomal storage disease or other         > $25 million but less than or equal to $50      [***]%
orphan drug (US) indication:                                                 million
                                                             > $50 million but less than or equal to        [***]%
                                                                           $100 million
                                                                          > $100 million                    [***]%

Has an Analogue of the Compound as an active component                 $25 million or less                  [***]%
and the indication is a lysosomal storage disease or       > $25 million but less than or equal to $50      [***]%
other orphan drug (US) indication:                                           million
                                                             > $50 million but less than or equal to        [***]%
                                                                           $100 million
                                                                          > $100 million                    [***]%

Has an Analogue of the Compound as an active component                 $25 million or less                  [***]%
and the indication is other than a lysosomal storage       > $25 million but less than or equal to $50      [***]%
disease or other orphan drug (US) indication:                                million
                                                             > $50 million but less than or equal to        [***]%
                                                                           $100 million
                                                                          > $100 million                    [***]%

Has neither the Compound nor an Analogue thereof as an                 $100 million or less                 [***]%
active component:                                                         > $100 million                    [***]%
</TABLE>

     Notwithstanding the foregoing, if (a) AMICUS THERAPEUTICS and/or its
     Affiliates (and/or appertaining sublicensees, as the case may be) is
     required to obtain from any Third Party that is not an Affiliate or a
     sublicensee any licenses and/or sublicenses for patent rights in order to
     practice NOVO NORDISK Intellectual Property Rights in the Field or in order
     to develop, make, have made, use, import, offer for sale, sell, import,
     export or provide Licensed Products (including, without limitation, as a
     result of any claim referred to in subsection (b)), or (b) any claim is
     made against AMICUS THERAPEUTICS and/or its Affiliates (and/or appertaining
     sublicensees, as the case may be) alleging that the practice of the NOVO
     NORDISK Intellectual Property Rights in the Field infringes any Third Party
     patent rights, then AMICUS THERAPEUTICS and/or its Affiliates (and/or
     appertaining sublicensees, as the case may be) shall be entitled to credit,
     in the case of subsection (a), any payment by AMICUS THERAPEUTICS and/or
     its Affiliates (and/or appertaining sublicensees, as the case may be) of
     additional running royalties to such Third Party(ies), if any, on Licensed
     Products, and, in the case of subsection (b), [***] of any
     reasonable costs and expenses

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       6
<PAGE>

     (including, without limitation, attorneys' fees, but excluding any
     judgments or any settlements in connection with such claims) incurred by
     AMICUS THERAPEUTICS and/or its Affiliates (and/or appertaining
     sublicensees, as the case may be) in connection with any such infringement
     claim against the running royalty for the subject Licensed Products, in the
     appertaining country(ies) during the appertaining time period. However, not
     withstanding the above the minimum royalty payable by AMICUS THERAPEUTICS
     and its Affiliates and sublicensees to NOVO NORDISK shall never be reduced
     below [***] of the royalties set forth in this Article 3.4, Table 1 and
     which are payable for Licensed Product in the specific country or countries
     in question.

3.5  All payments required under this Agreement shall be made in US Dollars to
     the following bank account or to such account as NOVO NORDISK may, from
     time to time, notify AMICUS THERAPEUTICS in writing:

     Danske Bank,
     Copenhagen
     Account number: [***] send via the correspondent bank:

     Bank of America N.A.
     New York
     SWIFT code: BOFAUS3N.

3.6  Royalty Accounting. The tiered royalties under this Agreement shall be paid
     quarterly but calculated on an annual basis. Only a single royalty rate
     shall be applicable in any given year and that rate will be determined by
     the total Annual Net Sales. An adjustment to prior quarters in any given
     year shall be made in any subsequent quarter of the same year in which a
     threshold in a higher royalty bracket has exceeded. A yearend adjustment
     will be made, if a royalty threshold is exceeded in the fourth quarter.

3.7  Payments and Reports. Royalties payable pursuant to this agreement shall be
     due quarterly within forty five (45) days following the end of each
     calendar quarter for Annual Net Sales in such calendar quarter. All sales
     in foreign currencies shall be converted into United States dollars using
     the rate of exchange quoted by Bank of America and its successor(s) on the
     last business day of the calendar quarter in which the sales were made.
     Each such payment shall be accompanied by a statement of Annual Net Sales
     for the quarter (including number of units), applicable exchange rates and
     the calculation of royalty payable hereunder by Licensed Product and
     country. AMICUS THERAPEUTICS shall keep and shall cause its Affiliates and
     sublicensees to keep complete, true and accurate records for at least five
     (5) years for the purpose of showing the derivation of all milestone
     payments and royalties payable under this Agreement.

     3.7.1 NOVO NORDISK duly accredited representatives, which are reasonably
          acceptable to AMICUS THERAPEUTICS, shall have the rights to inspect
          and audit such records at any time with reasonable prior notice to
          AMICUS THERAPEUTICS or any of its Affiliates or sublicensees, but such
          right will not be exercised more often than once a year.

     3.7.2 Any adjustment required as a result of an audit conducted under this
          Article shall be made within thirty (30) days after the date on which
          NOVO NORDISK completed the audit. In the event of an underpayment by
          AMICUS THERAPEUTICS, its Affiliates and/or sublicensees, AMICUS
          THERAPEUTICS shall pay to NOVO NORDISK the amount underpaid plus
          interest (calculated on a daily basis) on the overdue payment from the
          date such payment was due to the date of actual payment an annual rate

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       7
<PAGE>

          equal to the discount rate ("diskontoen") of the Danish National Bank
          plus 2% (two percent). In case of overpayment by AMICUS THERAPEUTICS,
          ifs Affiliates and/or sublicensees, AMICUS THERAPEUTICS may, at its
          option, offset any future royalty payments payable to NOVO NORDISK by
          the amount of the overpayment. Each Party shall have five (5) years
          after receipt by NOVO NORDISK of any royalty paid by AMICUS
          THERAPEUTICS, its Affiliates and/or sublicenses pursuant to this
          Agreement to dispute the amount of any such royalty payment.

3.8  Transfer of NOVO NORDISK Data. NOVO NORDISK will transfer, and will
     instruct its contractors about transfer, of NOVO NORDISK Data to AMICUS
     THERAPEUTICS after AMICUS THERAPEUTICS has given NOVO NORDISK a written
     notice that AMICUS wishes to receive such NOVO NORDISK Data. NOVO NORDISK's
     obligations on transfer of data will cease six (6) months after the
     Effective Date. After this date NOVO NORDISK will in good faith consider
     fulfilling requests from AMICUS THERAPEUTICS regarding additional
     information. NOVO NORDISK will charge AMICUS THERAPEUTICS the costs
     associated with such requests at a cost basis. The contact person at NOVO
     NORDISK will be head of Scientific Licensing, Pierre Honore
     (pfh@novonordisk.com).

3.9  AMICUS THERAPEUTICS shall deliver a written annual report on each
     anniversary of the Effective Date covering the preceding year regarding the
     status of the NOVO NORDISK Intellectual Property Rights and the Licensed
     Products identified, discovered or developed fully or partly through the
     use of Intellectual Property Rights by AMICUS THERAPEUTICS. Such annual
     report shall include, as a minimum; (a) identification by code number of
     Licensed Products identified, discovered or developed, using a method
     covered in whole or in part by the Intellectual Property Rights, or which
     reasonably could not have been identified, discovered or developed but for
     the Intellectual Property Rights or which are otherwise covered by the
     Intellectual Property Rights, unless AMICUS THERAPEUTICS provides
     contemporaneous written evidence to NOVO NORDISK that such identification,
     discovery or development took place before the date of issue or grant of
     relevant Intellectual Property Rights; (b) the status of any submissions to
     a regulatory agency in any country concerning Licensed Product; the
     identity of Third Parties that AMICUS THERAPEUTICS has granted sublicensees
     to under this agreement to; and, (c) such additional material as NOVO
     NORDISK may reasonably request. NOVO NORDISK shall maintain the
     confidentiality of all such reports and shall not use the information
     therein for any purpose other than determining compliance of AMICUS
     THERAPEUTICS with the terms of this Agreement.

3.10 The AMICUS THERAPEUTICS contact person responsible for communicating with
     the NOVO NORDISK under the reporting requirements of this Agreement shall
     be the same as is given in Article 16 (NOTICES), unless AMICUS THERAPEUTICS
     designates otherwise to NOVO NORDISK in writing.

3.11 All payments due under this Agreement shall be made without deduction other
     than such amount as AMICUS THERAPEUTICS is required to deduct or withhold
     by law. When making any payment due under this Agreement, AMICUS
     THERAPEUTICS shall also pay any value added (or similar) tax which is
     payable. The sums payable by AMICUS THERAPEUTICS are non-creditable and
     non-refundable. The previous sentences of this Article notwithstanding,
     each Party undertakes to cooperate with the other Party to achieve the tax
     arrangements that are most favourable for both Parties.

3.12 In the event of any delay in effecting the payments due under this
     Agreement by the due date, AMICUS THERAPEUTICS, its Affiliates and
     sublicensees agree to pay

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       8
<PAGE>

     to NOVO NORDISK interest (calculated on a daily basis) on the overdue
     payment from the date such payment was due to the date of actual payment an
     annual rate equal to the discount rate ("diskontoen") of the Danish
     National Bank plus 2% (two percent).

3.13 Under a purchase order separate from this Agreement, AMICUS THERAPEUTICS
     shall purchase and NOVO NORDISK shall sell and deliver to AMICUS
     THERAPEUTICS, [***] kg of the Compound, at a price of $[***] per gram. Such
     delivery shall be shipped no later than fifteen (15) calendar days after
     receipt of the purchase order. Payment terms and other terms for use of the
     Compound shall be established in such purchase order. NOVO NORDISK may
     require that a Materials Transfer Agreement is entered into in connection
     with such purchase.

4.   CONFIDENTIALITY

4.1  Neither Party shall publish, disclose or commit to any Third Party any
     information in whatever form concerning this Agreement and the license
     granted hereunder, nor shall it make any reference to this Agreement to any
     Third Party for five (5) years from the date of termination or expiration
     of this Agreement without the prior written consent of the other Party.

4.2  All information disclosed by one Party ("Disclosing Party") to the other
     Party ("Recipient") in oral, visual, written, or electronic form hereunder,
     including but not limited to, any technical or non-technical information
     concerning technical processes, specifications, instrumentation, chemical
     formulae, assays, techniques, sales and marketing information, material, or
     data related to this Agreement, ("Information"), shall be kept strictly
     confidential and shall not be disclosed by Recipient to any Third Party
     without the prior written and express consent of the Disclosing Party.
     Information disclosed in oral form shall be deemed Confidential Information
     only to the extent that it has been confirmed in writing to Disclosing
     Party and marked "confidential" within 30 (thirty) days after the date of
     oral disclosure.

4.3  Recipient shall not use the Information for any other purpose than
     performing its obligations under this Agreement; however AMICUS
     THERAPEUTICS shall be entitled to use Information for any regulatory
     purposes, including clinical trials.

4.4  The obligations of confidentiality described above in Articles 4.1 - 4.3
     shall not apply to

     a)   Information, which at the time of disclosure is already in the public
          domain;

     b)   Information, which, after disclosure, becomes part of the public
          domain through no violation of this Agreement;

     c)   Information, which Disclosing Party is able to prove has been
          disclosed to Recipient and which Recipient is able to prove has been
          in its possession of prior to disclosure. In this case, Recipient
          shall, in writing and within forty-five (45) days from the date of
          disclosure, demonstrate to the satisfaction of the Disclosing Party
          that it was in possession of such Information;

     d)   Information, which is hereafter lawfully disclosed by a Third Party to
          the Recipient, which Information such Third Party did not acquire
          under a still effective obligation of confidentiality to the
          disclosing Party;

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       9
<PAGE>

     e)   Information, which can be demonstrated as independently developed or
          acquired by Recipient without reference to or reliance upon
          confidential Information defined in this Agreement, and as evidenced
          by Recipient's written records;

     f)   Information disclosed to the extent required by law or regulation
          provided that Recipient shall give the Disclosing Party prompt written
          notice and sufficient opportunity to object, time permitting, to such
          disclosure.

4.5  Notwithstanding the foregoing, Recipient may disclose Information of the
     Disclosing Party to reliable employees, consultants and agents if necessary
     for exploiting the license granted under this Agreement or for a Party in
     order to fulfil its obligations under this Agreement, provided that such
     persons are bound by obligations of confidentiality and non-use to
     Recipient which are equal to the terms of this Agreement. Recipient shall
     ensure that such employees, consultants and agents be fully aware of the
     obligations of this Agreement and shall be responsible for any breach of
     these provisions by its employees, consultants and agents. Further, AMICUS
     THERAPEUTICS may disclose information relating to, or embodied by, NOVO
     NORDISK Intellectual Property Rights, as well as NOVO NORDISK Data to:
     manufacturing, distribution, marketing, co-development or other strategic
     or corporate partners or vendors, potential sublicensees, investors, board
     members, investment bankers, provided that such persons or entities are
     bound by obligations of confidentiality and non-use to AMICUS THERAPEUTICS
     which are equal to the terms of this Agreement. AMICUS THERAPEUTICS shall
     ensure that such persons or entities are fully aware of the obligations of
     this Agreement and shall be responsible for any breach of these provisions
     by such persons or entities.

5.   PUBLIC ANNOUNCEMENTS AND PUBLICATIONS

5.1  The Parties agree not to make, issue or release any public announcement,
     statement or acknowledgement of the existence of this Agreement without the
     prior written approval of the other Party. Such approval shall not be
     unreasonably withheld or delayed. NOVO NORDISK needs fourteen (14) calendar
     days for such approval.

5.2  The Parties agree that NOVO NORDISK has the rights to publish the papers as
     indicated in APPENDIX B.

6    PATENT FILING AND MAINTENANCE

6.1  NOVO NORDISK agrees to execute any and all papers necessary in connection
     with the applications set forth in Appendix A and any continuing
     divisional, reissue, reexamination or corresponding application thereof.

6.2  NNOVO NORDISK agrees to execute all papers necessary in connection with any
     interference which may be declared concerning the application or any
     continuing divisional, reissue, reexamination or corresponding application
     thereof and to cooperate with AMICUS THERAPEUTICS, in every reasonable way
     to obtain evidence and go forward with such interference.

6.3  AMICUS THERAPEUTICS shall be obliged at AMICUS THERAPEUTICS costs and
     expense to maintain and prosecute NOVO NORDISK Intellectual Property Rights
     until their expiry and AMICUS THERAPEUTICS shall have sole responsibility
     for the preparation, filing, prosecution, and maintenance of the
     Intellectual Property

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       10
<PAGE>

     Rights. AMICUS THERAPEUTICS shall in good faith consider input from NOVO
     NORDISK with respect to prosecution and maintenance. For the avoidance of
     doubt, AMICUS THERAPEUTICS will pay for the continued filing of
     Intellectual Property Rights concerning Licensed Products.

7    ENFORCEMENT OF INTELLECTUAL PROPERTY RIGHTS

7.1  Notification. Should NOVO NORDISK become aware that a Third Party has been
     or is threatening to infringe any of the Intellectual Property Rights, or
     that a Third Party is challenging the validity of any Intellectual Property
     Rights, NOVO NORDISK shall give AMICUS THERAPEUTICS prompt written notice
     detailing as many facts as possible concerning such infringement or
     potential infringement or challenge to validity.

7.2  Enforcement. AMICUS THERAPEUTICS shall at its own cost and expense be
     responsible for taking action as AMICUS THERAPEUTICS - in any event after
     consulting with NOVO NORDISK - may deem necessary to prevent an
     infringement of the Intellectual Property Rights; to enforce the
     Intellectual Property Rights and to defend the NOVO NORDISK Intellecutal
     Property Rights against any action challenging the validity of the NOVO
     NORDISK Patent Rights. No settlement shall be made unless with the prior
     written approval of NOVO NORDISK. Any sums recovered in a suit or
     settlement shall belong to AMICUS THERAPEUTICS. However, AMICUS
     THERAPEUTICES shall not name NOVO NORDISK as a coparty in the enforcement
     and defense of the Intellectual Property Rights without the express written
     consent of NOVO NORDISK and AMICUS THERAPEUTICS shall hold harmless NOVO
     NORDISK from all reasonable costs and expenses of such litigation,
     including reasonable attorney's fees. In the event NOVO NORDISK as the
     owner of the Intellectual Property Rights has to be joined in a suit, NOVO
     NORDISK shall have the right to be represented by a counsel of its own
     choice.

7.3  Obligations. AMICUS THERAPEUTICS shall be obligated to enforce any of the
     Intellectual Property Rights covered by this Agreement at its own expense.
     AMICUS THERAPEUTICS can partially be released from such obligation
     according to Article 12.2.

8    PATENT VALIDITY

8.1  If any claim challenging the validity or enforceability of any Intellectual
     Property Rights shall be brought against NOVO NORDISK, NOVO NORDISK shall
     promptly notify AMICUS THERAPEUTICS. Article 9.2 shall govern the
     disposition of any such claim.

8.2  If any Third Party challenges the validity or enforceability of any of the
     Intellectual Property Rights, AMICUS THERAPEUTICS agrees not to suspend any
     payments due to NOVO NORDISK until such time as that patent in Intellectual
     Property Rights is determined to be invalid or unenforceable by final
     judgement of a governmental agency or a court of competent jurisdiction
     from which no appeal can be or has been taken.

9    REPRESENTATIONS AND WARRANTIES

9.1  NOVO NORDISK represents and warrants that, to the best of its knowledge, it
     has the right to grant the license in and to Intellectual Property Rights
     set forth in this

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       11
<PAGE>

     Agreement, that the rights granted to AMICUS THERAPEUTICS, hereunder do not
     conflict with rights previously granted to any Third Party or any agreement
     to which NOVO NORDISK is bound, and that, to the best of its knowledge,
     there is no litigation pending or threatened with respect to the
     Intellectual Property Rights.

9.2  Nothing in this Agreement shall be construed as:

     9.2.1 A representation or warranty by NOVO NORDISK as to the patentability,
          validity, scope, or usefulness of Intellectual Property Rights; or

     9.2.2 A representation or warranty by NOVO NORDISK that anything made,
          used, sold, or otherwise disposed of under any license granted in this
          Agreement is or will be free from infringement of patents or other
          proprietary rights not included in Intellectual Property Rights.

9.3  EXCEPT AS EXPRESSLY SET FORTH ABOVE, NOVO NORDISK EXPRESSLY DISCLAIMS ANY
     AND ALL WARRANTIES, WHETHER EXPRESS OR IMPLIED, PERTAINING TO THE
     MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF THE INTELLECTUAL
     PROPERTY RIGHTS, LICENSED PRODUCTS, OR ANYTHING ELSE LICENSED, DISCLOSED,
     OR OTHERWISE PROVIDED TO AMICUS THERAPEUTICS UNDER THIS AGREEMENT. NOVO
     NORDISKS' TOTAL LIABILITY UNDER THIS AGREEMENT IS LIMITED TO THE COSTS AND
     FEES PAID BY AMICUS THERAPEUTICS TO NOVO NORDISK UNDER THIS AGREEMENT.

9.4  NOVO NORDISK warrants that NOVO NORDISK Data is transferred as is, i.e.
     AMICUS THERAPEUTICS will be responsible for finalising reports or document
     studies for the regulatory authorities. NOVO NORDISK will assist in tracing
     existing documents, data and or information available which are requested
     by such authorities under the terms and conditions described in Article
     3.8.

10   GOVERNING LAW AND DISPUTES

10.1 Both Parties will use their best efforts to settle all matters in dispute
     amicably. All disputes and differences of any kind related to this
     Agreement, which cannot be solved amicably by the Parties, shall be
     referred to arbitration as described below.

10.2 All disputes arising out of or in connection with the present contract
     shall be finally settled under the Rules of Arbitration of the
     International Chamber of Commerce by one or more arbitrators appointed in
     accordance with the said Rules.

10.3 The arbitration shall take place in London, England, and shall be conducted
     in the English language. The award of the arbitrators shall be final and
     binding on both Parties. The Parties bind themselves to carry out the
     awards of the arbitrators.

10.4 This contract shall be construed and interpreted pursuant to the laws of
     Denmark to the exclusion of any rule that would refer the subject matter to
     another forum. The English wording in this Agreement shall prevail.

11   TERM AND TERMINATION

11.1 This Agreement shall be in full force and effect from the Effective Date
     and shall remain in effect until expiry of the last to expire patent of
     Intellectual Property Rights, unless otherwise terminated by operation of
     law or pursuant to the terms and conditions of this Agreement.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       12
<PAGE>

11.2 Either Party may terminate this Agreement on thirty (30) days written
     notice to the other Party ("the Notified Party") if any of the following
     events occur:

     (a)  If the Notified Party is in breach of any of the material terms or
          obligations of this Agreement and such breach remains uncured for
          sixty (60) days following receipt by the Notified Party of written
          notice of such breach (if such default is cured within the cure
          period, such written notice shall be null and void), provided that, if
          the Notified Party can establish to the reasonable satisfaction of the
          other Party that it is diligently and actively pursuing a cure at the
          expiration of the cure period, and that the default is reasonably
          capable of being cured, then the cure period shall be extended for up
          to ninety (90) days from the date of receipt of the written notice of
          breach by the Notified Party. For the avoidance of doubt, in the event
          of a dispute whether a Party is in breach of the material terms and
          obligations of the Agreement and/or whether the cure period shall be
          extended, the dispute shall be resolved under Article 10. The
          Agreement shall not terminate until a final decision has been reached
          either by the Parties or under Arbitration as set forth in Article 10.

     (b)  In the event the Notified Party shall have become bankrupt, or shall
          have made an assignment for the benefit of its creditors or there
          shall have been appointed a trustee or receiver of the Notified Party
          or for all or a substantial part of its property or any case or
          proceeding shall have been commenced or other action taken by or
          against the Notified Party in bankruptcy or seeking reorganization,
          liquidation, dissolution, winding-up, arrangement, composition or
          readjustment of its debts or any other relief under any bankruptcy,
          insolvency, reorganization, or other similar act or law of any
          jurisdiction now or hereafter in effect and any such event shall have
          continued for ninety (90) days undismissed, unbonded and/or
          undischarged. All rights and license granted under this Agreement by
          one Party to the other Party are, and shall otherwise be deemed to be,
          for purposes of Section 365(n) of the Bankruptcy Code, license of
          rights to "intellectual property" as defined under Section 101 (56) of
          the Bankruptcy Code. The Parties agree that the licensor under this
          Agreement shall retain and may fully exercise all of its rights and
          elections under the Bankruptcy Code in the event of a bankruptcy by
          the other Party. The Parties further agree that in the event of the
          commencement of a bankruptcy proceeding by or against one Party under
          the Bankruptcy Code of their respective countries, the other Party
          shall be entitled to complete access to any such intellectual property
          pertaining to the rights granted in the licenses hereunder of the
          Party by or against whom a bankruptcy proceeding has been commenced
          and all embodiments of such intellectual property. However, if NOVO
          NORDISK is the bankrupt party, this above shall only apply to the
          extent this is allowed under the Danish Bankruptcy Code
          ("Konkursloven").

11.3 Lack of payments due to NOVO NORDISK under this License Agreement or in
     relation to maintenance, defending and enforcing the Intellectual Property
     Rights shall always be considered material breach.

11.4 AMICUS THERAPEUTICS may terminate this License Agreement in its entirety at
     any time upon one hundred and eighty (180) days written notice to NOVO
     NORDISK.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       13
<PAGE>

11.5 This Agreement, and the license granted to AMICUS THERAPEUTICS, may be
     terminated with effect immediately by NOVO NORDISK in the event that AMICUS
     THERAPEUTICS either directly or indirectly opposes, or assists any Third
     Party to oppose, the grant of any of the Intellectual Property Rights or
     disputes, or directly or indirectly assists any Third Party to dispute, the
     validity of any of the NOVO NORDISK Intellectual Property Rights.

11.6 The provisions under which this Agreement may be terminated shall be in
     addition to any and all other legal remedies which either Party may have
     for the enforcement of any and all terms hereof, and do not in any way
     limit any other legal remedy such Party may have.

11.7 Termination of this Agreement shall terminate all rights and licenses
     granted to AMICUS THERAPEUTICS relating to the Intellectual Property
     Rights.

12   TERMINATION OF CERTAIN INTELLECTUAL PROPERTY RIGHTS

12.1 AMICUS THERAPEUTICS shall be entitled to give NOVO NORDISK a written notice
     of ninety (90) days that AMICUS THERAPEUTICS wishes to exclude certain NOVO
     NORDISK Intellectual Property Rights from the license granted under this
     Agreement. In this case those NOVO NORDISK Intellectual Property Rights
     excluded from the license granted under this Agreement shall revert to NOVO
     NORDISK. The Parties shall enter into an amendment to this Agreement
     stating that Intellectual Property Rights continue to be included in the
     Agreement. The license granted under this Agreement shall continue to be in
     full force and effect with respect to this remaining part of the
     Intellectual Property Rights.

13   RIGHTS AND DUTIES UPON EXPIRATION OR TERMINATION

13.1 Upon termination of this Agreement, NOVO NORDISK shall have the right to
     retain any sums already paid by AMICUS THERAPEUTICS hereunder.

13.2 Expiration or termination of this Agreement shall terminate all outstanding
     grants, obligations and liabilities between the Parties arising from this
     Agreement, except those described in Articles 4, 5, 11.6, 11.7, 13, 14, 15
     and 17 which shall survive expiration or any termination of the Agreement

13.3 The grant under Article 3 of this Agreement shall cease by termination of
     this Agreement and AMICUS THERAPEUTICS shall return its rights to NOVO
     NORDISK Intellectual Property Rights to NOVO NORDISK.

14   USE OF NAMES

14.1 Nothing contained in this Agreement shall be construed as conferring any
     rights to use in advertising, publicity or other promotional activities any
     name, trade name, trademark, or other designation of a party hereto,
     including any contraction, abbreviation, or simulation of any of the
     foregoing, unless the express written permission of the other party has
     been obtained. Each party hereby agrees not to use the names of the other
     party without prior written approval from such other party.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       14
<PAGE>

15   INDEMNIFICATION

15.1 AMICUS THERAPEUTICS agrees to indemnify, hold harmless, and defend NOVO
     NORDISK, its officers, employees and agents against any and all claims,
     suits, losses, damages, costs, fees and expenses resulting from or arising
     out of exercise of this Agreement, including, but not limited to, any
     damages, losses, or liabilities whatsoever with respect to death or injury
     to any person and damage to any property arising from the possession, use,
     or operation of Intellectual Property Rights by AMICUS THERAPEUTICS,
     including any infringement by AMICUS THERAPEUTICS of the intellectual
     property of a Third Party through AMICUS THERAPEUTICS' use or operation of
     Intellectual Property Rights. NOVO NORDISK shall indemnify AMICUS
     THERAPEUTICS in like manner with respect to any breach of the
     representations and warranties set forth in Article 9.

16   NOTICES

16.1 Any notice or other communication required or permitted to be given by
     either Party hereto shall be deemed to have been properly given and be
     effective upon the date of delivery if delivered in writing to the
     respective addresses set forth below, or to such other address as either
     party shall designate by written notice given to the other Party. If notice
     or other communication is given by facsimile transmission, said notice
     shall be confirmed by prompt delivery of the hard-copy original.

     If to NOVO NORDISK:        Attn: Pierre Honore,
                                Vice President Scientific Licensing
                                NOVO NORDISK A/S
                                Novo Alle
                                DK-2880 Bagsvaerd
                                Denmark
                                Fax: +45 44 42 13 13
                                Phone: +45 44 42 71 44

     with a copy to:            NOVO NORDISK A/S
                                Corporate Legal

                                Attn.: General Counsel
                                NOVO NORDISK A/S
                                Novo Alle
                                DK-2880 Bagsvaerd
                                Denmark
                                Fax: +45 44 98 06 70

     If to AMICUS THERAPEUTICS:

                                Attn.: John F. Crowley
                                Amicus Therapeutics, Inc.
                                President and CEO
                                675 U.S. Highway One
                                No. Brunswick, New Jersey USA 08902

     with a copy to:

                                Att.: Douglas A. Branch
                                Biotech Law Associates, P.C.
                                800 Research Parkway, Suite 310
                                Oklahoma City, Oklahoma USA 73104

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       15
<PAGE>

     Or such other address as either Party may request in writing.

17   INSURANCE REQUIREMENTS

17.1 AMICUS THERAPEUTICS shall maintain general liability insurance including
     product liability and contractual liability coverage within the limits tied
     to the risks inherent in use of the Intellectual Property Rights. AMICUS
     THERAPEUTICS must declare whether the insurance is provided on a claims
     made form and must notify NOVO NORDISK if coverage is cancelled. If
     coverage is maintained by AMICUS THERAPEUTICS on Licensed Product(s) after
     termination or expiration of this Agreement, such coverage must continue to
     name NOVO NORDISK.

17.2 AMICUS THERAPEUTICS shall list NOVO NORDISK as an additional insured under
     each liability policy that AMICUS THERAPEUTICS shall have or obtain that
     includes coverage of claims relating to products or processes used, made or
     sold as a result of AMICUS THERAPEUTICS'exercise of the Intellectual
     Property Rights. This insurance clause shall survive the termination of
     this Agreement.

18   GENERAL

18.1 Assignment. The License Agreement may not be assigned by either party
     without the other party's consent. In the event a party gives its consent
     to an assignment of the License Agreement, the assignee shall not be
     entitled to exercise any rights or receive any benefits under the License
     Agreement until it has expressly assumed in writing to the other party the
     performance and obligations of all the assigning party's duties and
     obligations as set forth in the License Agreement. No such consent of the
     other party will be required for assignment of the License Agreement (a) in
     connection with the transfer or sale of all or substantially all of the
     business of such party to which the agreement relates to a Third Party,
     whether by merger, sale of stock, sale of assets or otherwise, or (b) to
     any Affiliate. However, in the event of assignment to a successor by merger
     or by sale of all or substantially all of a party's assets, such successor
     shall not be entitled to exercise any rights or receive any benefits from
     this License Agreement until it has expressly assumed in writing to the
     other party the performance and obligations of all the assigning party's
     duties and obligations as set forth in the License Agreement. Any
     assignment of the License Agreement which is not in accordance with the
     aforementioned shall be void.

18.2 AMICUS THERAPEUTICS shall have the rights to assign or transfer any or all
     of its rights or obligations under this Agreement at any time after AMICUS
     THERAPEUTICS has paid the consideration set forth in Article 3.3.a, so long
     as the obligations in Article 18.1. are fulfilled.

18.3 Article headings in this Agreement are for convenience only and do not
     affect its interpretation.

18.4 In the event that one or more provisions of this Agreement are invalid for
     any reason, the validity of the remaining provisions of this Agreement
     shall not be affected. The Parties agree to replace such invalid provisions
     or any gaps in the Agreement that might become evident, by new, valid
     provisions that correspond as closely as possible to the intended purpose
     of this Agreement.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       16
<PAGE>

18.5 The Confidentiality Agreement dated March 1st, 2005, the Stand Still
     Agreement dated April 1st, 2005 and the Material Transfer Agreement dated
     4th of April, 2005 shall continue to be in full force and effect until the
     Effective Date of this Agreement on which date those agreements shall be
     terminated. Provisions of such agreements which according to the wording of
     the agreements survive termination shall continue to be in full force and
     effect notwithstanding the aforementioned termination.

18.6 No Waiver. The failure of any Party to enforce at any time any provision of
     this Agreement, or any right with respect thereto, or to exercise any
     election herein provided, shall in no way be considered to be a waiver of
     such provision, right or election, or in any way affect the validity of
     this Agreement. The exercise by any Party of any right or election under
     the terms or covenants herein shall not preclude or prejudice any party
     from exercising the same or any other right it may have under this
     Agreement, irrespective of any previous action or proceeding taken by the
     Parties hereunder.

18.7 Severability. Should a court of competent jurisdiction later consider any
     provision of this Agreement to be invalid, illegal, or unenforceable, it
     shall be considered severed from this Agreement. All other provisions,
     rights, and obligations shall continue without regard to the severed
     revision, provided that the remaining provisions of this Agreement are in
     accordance with the intention of the parties.

18.8 Amendment. This Agreement may only be amended in writing signed by duly
     authorised representatives of AMICUS THERAPEUTICS and NOVO NORDISK.

18.9 Interpretation. In this Agreement the headings are used for convenience
     only and shall not affect its interpretation. References to the singular
     include the plural and vice versa.

18.10 Further Action. Each party agrees to execute, acknowledge and deliver such
     further instruments, and do all further similar acts, as may be necessary
     or appropriate to carry out the purposes and intent of this Agreement.

18.11 Entire Agreement. Subject to Article 18.5 this Agreement sets out the
     entire agreement between the Parties relating to its subject matter and
     supersedes all prior oral or written agreements, arrangements or
     understandings between them relating to such subject matter. The
     confidentiality agreement, this exclusive license agreement and any
     amendments hereto are signed by AMICUS THERAPEUTICS on behalf of the
     company itself and its US based Affiliates.

18.12 Costs. Each party shall pay their own costs in connection with entering
     into this Agreement.

18.13 Counterparts. This Agreement may be executed in two or more counterparts,
     each of which shall be deemed an original, but all of which together shall
     constitute one and the same instrument.

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       17
<PAGE>

     IN WITNESS WHEREOF, the Parties hereto have caused this instrument to be
     executed in duplicate by their duly authorized representatives as of the
     date stated below.

Date: 5/26/05                           Date: 6/8/2005
AMICUS THERAPEUTICS, INC.               NOVO NORDISK A/S

/s/ John F. Crowley                     /s/ Peter Kurtzhals
-------------------------------------   ----------------------------------------
By: John F. Crowley                     By: Peter Kurtzhals
Title: Chairman and Chief Executive     Title: Senior Vice President and
       Officer                                 Head of Discovery

                                        /s/ Pierre Honore
                                        ----------------------------------------
                                        By: Pierre Honore
                                        Title: Vice President, Scientific
                                               Licensing

                                                                              18
<PAGE>

                                   APPENDIX A
                    ACTIVE PATENT FAMILIES RELATING TO NN4201

<TABLE>
<CAPTION>
CASE NO.      PRIORITY DATE                           SCOPE                               ACTIVE MEMBERS
--------   ------------------   -------------------------------------------------   --------------------------
<S>        <C>                  <C>                                                 <C>
4172       March 9, 1994        EPO: Compounds of the formula (CHEMICAL FORMULA)    EP patent: CH, DE, FR, GB,
                                US: Pharmaceutical compositions comprising          SE (EP 749423)
                                (CHEMICAL FORMULA) or (CHEMICAL FORMULA)            US 5,863,903
                                Methods of treating diabetes or reducing liver      JP application
                                glucose production using said compositions

4573       September 8, 1995    EPO: Use of a compound of the formula (CHEMICAL     EP 858335 in force in CH,
                                FORMULA) in the manufacture of medicaments for      DE, FR, GB, SE.
                                inhibiting liver glucose production or inhibiting
                                liver glycogen phosphorylase. 42-1001               US 5,854,272
                                specifically for manufacturing of medicaments for   US 6,541,836
                                diabetes
                                                                                    JP 3043430

                                US 5,854,272: A method of treating diabetes or
                                inhibiting liver glucose production by
                                administration of a (CHEMICAL FORMULA) compound
                                of the formula

                                US 6,541,836: A method or inhibiting liver
                                glycogen phosphorylase by administration of a
                                compound of the formula
                                (CHEMICAL FORMULA)
5243       May 6, 1997          Compounds of the formula                            US 6,046,214
                                (CHEMICAL FORMULA)
5841       March 15, 1999       Tatrate salt of 42-1001                             EP, JP applications
                                                                                    US 6,316,489
</TABLE>

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       19
<PAGE>

<TABLE>
<CAPTION>
CASE NO.      PRIORITY DATE                           SCOPE                               ACTIVE MEMBERS
--------   ------------------   -------------------------------------------------   --------------------------
<S>        <C>                  <C>                                                 <C>
5842       March 15,1999        Napsylate salt of 42-1001                           EP, JP applications
                                                                                    US 6,239,163

5941       September 29, 1999   Compounds of the formula (CHEMICAL FORMULA)         EP, JP and US applications
                                                                                    US 6,590,118

6261       November 8, 2000     Compositions comprising 41-1001 and other           Only in Denmark
                                anti-diabetica

                                NB Utility model

6474       October 28, 2002     The use of compounds of formula                     Applications in US and PCT
                                (CHEMICAL FORMULA), (CHEMICAL FORMULA), or          WO 04/037233
                                (CHEMICAL FORMULA) in the treatment of early
                                cardiac diseases
</TABLE>

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       20
<PAGE>

APPENDIX B

<TABLE>
<CAPTION>
NN4201 PUBLICATIONS    Responsible         Data on Compound       Authors (Initials) in random order       Journal
-------------------   -------------   -------------------------   ----------------------------------   ----------------
<S>                   <C>             <C>                         <C>                                  <C>
Safety package        Klaus Ryetved   All safety data on          KRYT, BEKI, NILD                     Arzneimittel /
                                      Compound                                                         Drug research

In vitro              Klaus Ryetved   VF/ECG data on Pathology,   KRYT, INSJ, NCBN, KF, (?)            Br. J. Pharmacol
                                      glycogen, and enzyme

In vivo/AMI           Niels C Berg    Biotrial report             BEKI, KF, KRYT, NCBN                 Circulation
                      Nyborg                                      and study director from Biotrial

Comparison to other   Keld Fosgerau   Comparison of data from     KRYT, NCBN, KF, BFH+ ?               Br. J. Pharmacol
compounds                             heart, including isolated
                                      muscle data.
</TABLE>

<TABLE>
<CAPTION>
                                                            Authors (Initials) in
NN4201 ABSTRACTS       Responsible       Data on Compound        random order        Journal
----------------   -------------------   ----------------   ---------------------   --------
<S>                <C>                   <C>                <C>                     <C>
In vitro           Keld Fosgerau         In vitro           KF, KRYT, NCBN?         ADA

In vivo            Niels C Berg Nyborg   In vivo            KF, KRYT                ADA
                                                            NCBN+?
</TABLE>

[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
      TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED
      WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2
      PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                                       21<PAGE>

                                                                    EXHIBIT 10.7

                               SUBLEASE AGREEMENT

                                     BETWEEN

                         PURDUE PHARMA, L.P, SUBLESSOR

                                       AND

                      AMICUS THERAPEUTICS, INC., SUBLESSEE

Building Address:      6 Cedar Brook Drive
                       Cranbury, New Jersey 08512

Subleased Premises:    A Portion of the First Floor and
                       The Entire Second Floor
<PAGE>

                               SUBLEASE AGREEMENT

      SUBLEASE AGREEMENT ("SUBLEASE") made as of this 12 day of May, 2005, by
and between PURDUE PHARMA L.P., a Delaware limited partnership having an office
at One Stamford Forum, Stamford, CT 06901-3413 ("SUBLESSOR") and AMICUS
THERAPEUTICS, Inc., a Delaware corporation having an office at 675 US Hightway
One, North Brunswick, NJ 08902 ("SUBLESSEE").

                                   WITNESSETH:

      WHEREAS, pursuant to a Lease Agreement dated as of December 13, 2000 (the
"PRIME LEASE"), between Cedar Brook 10 Corporate Center, L.P., as landlord
("LANDLORD"), and Sublessor, as tenant, Landlord leased to Sublessor certain
premises containing approximately 114,486 rentable square feet (the "PREMISES"),
in the building located at 6 Cedar Brook Drive, Cranbury, New Jersey 08512 (the
"BUILDING").

      WHEREAS, Sublessor desires to sublease to Sublessee and Sublessee desires
to sublease from Sublessor a portion of the Premises, consisting of a portion
of the first floor and the entire second floor of the Building, containing
approximately 31,906 rentable square feet which is made up of 12,293 rentable
square feet of laboratory space (the "LAB SPACE"), 11,308 rentable feet of
office space (the "OFFICE SPACE") and 8,305 rentable square feet of
unfinished(the "UNFINISHED SPACE") and shown outlined on the Floor Plan annexed
hereto as EXHIBIT A, and made a part hereof (collectively the "SUBLEASED
PREMISES"), on the terms, covenants and conditions hereinafter provided,

      NOW, THEREFORE, Sublessor and Sublessee covenant and agree as follows:

1.    SUBLEASE.

      (a) Sublessor hereby subleases to Sublessee, and Sublessee hereby hires
and subleases from Sublessor, the Subleased Premises.

      (b) The parties acknowledge and agree that for all purposes of this
Sublease, as of the Commencement Date (hereafter defined) (i) the Subleased
Premises conclusively shall be to contain 31,906 rentable square feet, (ii) the
Lab Space conclusively shall be deemed to contain 12,293 rentable square feet,
(iii) the Office Space conclusively shall be deemed to contain 11,308 rentable
square feet, and (iv) the Unfinished Space conclusively shall be deemed to
contain 8,305 rentable square feet.

2.    TERM.

      (a) The term (the "TERM") of this Sublease shall commence on the date
which is the later to occur of (i) the date when this Sublease has been fully
executed and delivered by both Sublessor and Sublessee, (ii) the date Sublessor
notifies Sublessee it has received the consent of the Landlord or Landlord's
consent was deemed given and (iii) the date that possession of the Subleased
Premises are provided to Sublessee (the "COMMENCEMENT DATE"), and shall expire
on February 28, 2012 or on such earlier date upon which the Term may expire or
terminate pursuant to any provision set forth herein (the "EXPIRATION DATE"). It
is expressly understood and agreed

<PAGE>

that Sublessee shall have no rights whatsoever to extend the Term and/or expand
the Subleased Premises, except as otherwise set forth in Section 29 of this
Sublease.

      (b) After the Commencement Date, Sublessee and Sublessor shall execute a
memorandum, in a form reasonably acceptable to both parties, memorializing the
Commencement Date. Notwithstanding the foregoing, Sublessee agrees that failure
or omission to execute such a memorandum will not effect the Commencement Date.

3.    BASE RENT.

During the entire Term, Sublessee shall pay Sublessor, as rent for each part of
the Subleased Premises, the following annual sums ("BASE RENT"), in equal
monthly installments, in advance on the first day of each month, without setoff
or deduction whatsoever (except to the extent otherwise specifically set forth
herein):

LAB SPACE AND
OFFICE SPACE:
<TABLE>
<CAPTION>
                                                                                 Annual Base Rent
                                                                                 Rate Per Rentable
          Period                     Annual Base Rent      Monthly Base Rent        Square Foot
--------------------------           ----------------      -----------------     -----------------
<S>                                  <C>                   <C>                   <C>
From the Commencement Date             $ 660,828.00            $ 55,069.00           $ 28.00
through and including
February 28, 2007

From March 1, 2007 through             $ 759,952.20            $ 63,329.35           $ 32.20
and including the
Expiration Date
</TABLE>

UNFINISHED
  SPACE:

<TABLE>
<CAPTION>
                                                                                 Annual Base Rent
                                                                                 Rate Per Rentable
          Period                     Annual Base Rent      Monthly Base Rent        Square Foot
--------------------------           ----------------      -----------------     -----------------
<S>                                  <C>                   <C>                   <C>
From the Commencement Date             $ 141,185.00            $ 11,765.42           $ 17.00
through and including
February 28, 2007

From March 1, 2007 through             $ 153,642.50            $ 12,803.54           $ 18.50
and including the
Expiration Date
</TABLE>

                                       2

<PAGE>

Notwithstanding the foregoing, Sublessor hereby grants Sublessee an abatement
of the Base Rent only (such abatement specifically excluding any additional
rent) for (i) the Lab Space and Office Space for the period commencing on the
Commencement Date and expiring on the date which is sixty (60) days next
following the Commencement Date and (ii) the Unfinished Space for the period
commencing on the Commencement Date and expiring on the date which is one
hundred and eighty (180) days next following the Commencement Date (the
"ABATEMENT PERIODS"), provided that no Event of Default has occurred and the
Sublease remains in full force and effect. In the event Sublessee shall default
with respect to any of its obligations under this Sublease at any time during
the Term of this Sublease, in addition to all of Sublessor's right and remedies
under This Sublease, Sublessor shall be entitled to full payment of Base Rent
for the Abatement Periods.

It the Commencement Date occurs on a day which is not the first day of a
calendar month, or if the Expiration Date occurs on a day which is not the last
day of a calendar month, then the Base Rent payable under this Sublease for such
month shall be appropriately adjusted so that Sublessee pays Base Rent only for
the portion of such calendar month occurring within the Term.

4.    ADDITIONAL RENT.

In addition to the Base Rent under Section 3 above, Sublessee shall pay
Sublessor additional rent as follows:

      (a) Operating Expense Payments. Commencing from and after the Commencement
Date, Sublessee shall pay to Sublessar, as additional rent, in equal monthly
installments, in advance on the first day of each month, (prorated for any
partial month) without setoff or deduction whatsoever the annual sum of
$332,944.45 ($27,745.38 per month; $10.50 per rentable square foot of the
Subleased Premises) (the "FIXED OPERATING EXPENSE CHARGE") as payment to
Sublessor for Sublessor's costs of operating and maintaining the Building.
Beginning on the first anniversary of the Commencement Date and on each
successive anniversary thereafter during the Term (the "ADJUSTMENT DATES") the
Fixed Operating Expense Charge shall be increased by three percent (3%) over the
Fixed Operating Expense Charge in effect for the period immediately preceding
the applicable Adjustment Date.

      (b) Real Estate Taxes and Landlord Common Charge.

            (i) Commencing from and after the Commencement Date, Sublessee shall
pay to Sublessor, as additional rent (prorated for any partial month)
without setoff or deduction whatsoever, an amount (the "TAX AND COMMON
CHARGE AMOUNT") equal to the Sublessee's proportionate share (i.e. 27.87%)
of the Sublessor's payments to Landlord under Article 8 of the Prime
Lease. Sublessee shall pay the Tax and Common Charge Amount to Sublessor within
thirty (30) days after the rendition of a bill thereof by Sublessor, from time
to time.

                                       3

<PAGE>

      (c) Electricity. Sublessee's costs for electrical current consumed in the
Subleased Premises is included in the Fixed Operating Expense Charge, but may be
increased pursuant to the terms of Section 6 herein.

      (d) Lab Gasses. Sublessee's costs for compressed air and natural gas
consumed in the Subleased Premises is included in the Fixed Operating Expense
Charge, but may be increased pursuant to the terms of Section 6 herein.

      (e) License Fee. Sublessee shall pay the Temp Lab Operating Expense Charge
as provided in Section 35 of this Sublease in the same manner as the Fixed
Operating Expense Charge.

      (f) Sums Due as Additional Rent. All sums of money (except for Base Rent)
as shall become due from Sublessee to Sublessor hereunder shall be deemed
additional rent. If Sublessee fails to make any payment of additional rent when
due, Sublessor shall have (in addition to all other remedies) the same rights
and remedies with respect thereto as provided in this Sublease(including,
without limitation, the provisions of the Prime Lease incorporated by reference)
for nonpayment of Base Rent or additional rent.

5.    RENT PAYMENTS.

      (a) All Base Rent, additional rent and other charges payable by Sublessee
to Sublessor under this Sublease shall be paid to Sublessor at the following
address:

                Purdue Pharma, L.P.
                One Stamford Forum
                Stamford, CT 06901
                Attention: James O'Brien, Chief Accountant

or such other place, or to such agent and at such place, as Sublessor may
designate by notice to Sublessee. Notwithstanding anything to the contrary set
forth herein, Sublessee shall pay the first installment of Monthly Base Rent,
the Fixed Operating Expense Charge, Tax and Common Charge Amount and Security
Deposit (as hereinafter defined) simultaneously with the execution and delivery
of this Sublease by Sublessee to Sublessor.

      (b) Notwithstanding the foregoing, Sublessee, at its election, may pay
any item of Base Rent, additional rent or other charges payable by Sublessee to
Sublessor under this Sublease by wire transfer made to such account as Sublessor
may have contemporaneously herewith designated in writing.

      (c) From time to time during the Term, Sublessor may designate a new
address and/or wire transfer account for payment of the aforesaid items by
giving reasonable prior written notice thereof to Sublessee in accordance with
the provisions of Section 19 hereof.

                                       4

<PAGE>

6.    UTILITY SERVICES.

      (a) Costs for consumption of electrical current, lab gasses, HVAC (as
hereinafter defined in Section 18) and other utilities in the Subleased Premises
are included in the Fixed Operating Expense Charge based on the use of the
Subleased Premises in strict conformity with the Permitted Use (as hereinafter
defined in Section 8). If the use of the Subleased Premises is not in strict
conformity with the Permitted Use, Sublessee shall, within thirty (30) days
after the rendition of a bill thereof by Sublessor, from time to time, pay
Sublessor for any additional costs incurred by Sublessor for such other use
including, without limitation, increased utility costs, Nothing herein shall be
deemed to allow Sublessee to use the Subleased Premises for any use other than
the Permitted Use.

      (b) Notwithstanding anything to the contrary in this Sublease, Sublessee
shall be entitled to HVAC service pursuant to the terms of Section 18 based upon
usage solely from the existing (as of the date of this Sublease) air handling
equipment serving the Subleased Premises. Sublessee shall pay for any additional
air handlers or additional HVAC service installed in or supplied to the
Subleased Premises, including without limitation, costs to submeter the
Subleased Premises, at Sublessee's sole cost and expense. Nothing herein shall
be deemed to allow Sublessee to install and/or use any additional air handling
equipment or HVAC service without Sublessor's consent which consent shall not be
unreasonably withheld provided such equipment or services (i) are consistent and
compatible with the existing Building HVAC systems, (ii) Landlord has approved
the installation of such services and (iii) Sublessee has complied with the
terms of Section 15 of this Sublease and all applicable terms of the Prime Lease
with respect to such equipment or services. If Sublessor, in its sole
discretion, shall supply any additional HVAC service, Sublessee shall pay the
costs thereof to Sublessor within thirty (30) days after the rendition of a bill
thereof by Sublessor, from time to time.

7.    OBLIGATION TO IMPROVE.

Sublessee shall improve the Unfinished Space, and cause it to be constructed, at
Sublessee's sole cost and expense, as a chemistry and biology lab in a manner
that is architecturally similar to the improvements currently existing in the
Building. Such improvements shall comply with all laws (as hereinafter defined)
and the terms of Section 15 hereof. Sublessee shall obtain Sublessor's consent
to the plans and specifications for such improvements pursuant to the terms of
Section 15 hereof. Sublessee shall commence the construction of the Unfinished
Space immediately after the Commencement Date and approval by Sublessor of the
plans and specifications for such construction and diligently pursue such
construction to completion. Sublessee shall complete the construction to the
Unfinished Space as required herein, on or prior to the nine (9) month
anniversary of the Commencement Date.

8.    USE

      (a) Sublessee (and any permitted occupants of the Subleased Premises)
shall use and occupy (i) the Lab Space as a customary biology and chemistry
laboratory, (ii) the Office Space for customary, general office use and (iii)
the Unfinished Space for a customary biology and chemistry laboratory,
(collectively, the "PERMITTED USE") provided however that each Permitted

                                       5
<PAGE>
Use is subject to all applicable zoning or other ordinances, rules, regulations,
orders, decrees, statues and laws of any governmental entity, board, or bureaus
(collectively "LAWS") and in no event shall Sublessee use or permit the use of
the Subleased Premises or any part thereof in any manner or for any purpose
which is not permitted under and consistent with the provisions of the Prime
Lease or as a vivarium. For purposes of this Sublease, the terms "customary
biology and chemistry laboratory" shall consist of customary research and
development for the operation of Sublessee's business but shall specifically
exclude (i) any chemical or biological production for commercial sale, (ii) BL3
or BL4 activities as classified by the US Center for Disease Control and (iii)
the housing of or experimentation with live animals of any kind.

      (b) Sublessee shall, at its sole cost and expense, shield all equipment
which generates or produces any electro-magnetic fields or emissions or wireless
communication devices so that all generated fields are reasonably contained
solely within the Subleased Premises and do not create any interference outside
the Subleased Premises. If Sublessee fails to shield all such equipment or
devices, Sublessee shall immediately remove and cease operation of such
equipment or devices within three (3) days after rendition of notice from
Sublessor to Sublessee advising Sublessee to remove such equipment or device.

9. CONDITION OF SUBLEASED PREMISES.

      (a) Sublessee acknowledges that Sublessee is hiring the Subleased Premises
in "as-is" condition as of the date hereof. In making and executing this
Sublease, Sublessee has not relied upon or been induced by any statements or
representations of any person with respect to the physical condition of the
Subleased Premises. Sublessee has relied solely on its own investigations,
examinations and inspections of the Subleased Premises.

      (b) Notwithstanding the provisions of Section 9(a) above, Sublessor hereby
agrees to deliver the Subleased Premises to Sublessee on the Commencement Date
in broom clean condition, including any and all fixtures, furniture and
furnishings (the "FURNITURE") existing within the Subleased Premises on the
Commencement Date which Sublessee shall accept in its "as is" condition on the
Commencement Date.

10. SUBORDINATION.

Sublessor and Sublessee agree that this Sublease is, and shall be, subject and
subordinate to all of the terms, covenants and conditions of the Prime Lease,
and to the matters to which the Prime Lease shall be subordinate. This Section
shall be self operative and no further instrument of subordination shall be
required to effectuate this provision.

11. INCORPORATION OF PRIME LEASE TERMS.

      (a) The terms, covenants and conditions of the Prime Lease are
incorporated herein by reference so that, except as set forth in Section 11 (b)
below or elsewhere in this Sublease, and except to the extent that such
incorporated provisions are inapplicable to or modified by Section 11(c)below or
other provisions of this Sublease (all such incorporated provisions, and all
such incorporated provisions as so modified, are herein called the "INCORPORATED
PROVISIONS"), all of

                                       6
<PAGE>
 the terms, covenants and conditions of the Prime Lease which bind or inure to
the benefit of the Landlord thereunder shall, in respect of this Sublease, bind
or inure to the benefit of Sublessor, said all of the terms, covenants and
conditions of the Prime Lease which bind or inure to the benefit of the Tenant
thereunder shall, in respect of this Sublease, bind or inure to the benefit of
Sublessee, with the same force and effect as if such incorporated terms,
covenants and conditions were completely set forth in this Sublease, and as if
the words "landlord" and "tenant" or words of similar import, wherever the same
appear in the Prime Lease, were construed to mean, respectively, "Sublessor" and
"Sublessee" in this Sublease, and as if the words "premises," "occupied
premises", "property" and "demised premises" or words of similar import,
wherever the same appear in the Prime Lease, were construed to mean "Subleased
Premises" in this Sublease, and as if the word "lease" or words of similar
import, wherever the same appear in the Prime Lease, were construed to mean this
"Sublease" except that references to "Occupied Premises" in Article 7 of the
Prime Lease shall be deemed to refer to the "Subleased Premises" only and
references to "Landlord" therein shall be deemed to refer to Landlord and not
Sublessor. Sublessee shall not do, or permit to be done, any act or thing that
would result in an increase in any of the rents, additional rents, or any other
sums or charges payable by Sublessor under the Lease or any other obligation or
liability of Sublessor under the Lease or that is (or, with notice and/or the
passage of time, would be) a default under the Lease.

      (b) The following provisions of the Prime Lease shall not be incorporated
herein by reference and shall not apply to this Sublease: the preamble and
witness statements; Article 1; Article 2; Article 3 except Sections 3.12 (a) and
(b) and except that Sublessee shall comply with Section 3.12 and all references
to "Landlord" in these Sections shall be deemed to refer to Landlord and not
Sublessor; Articles 4 - 6; the third sentence in Section 7.1, the first and
second sentences in Section 7.2; Article 8; Article 9 except that any signage
proposed by Sublessee shall be in compliance with Section 33 of this Sublease;
Articles 10-11; Sections 12.1(a)(ii)and b(ii), the penultimate sentence in
Section 12.3, the eleventh sentence in Section 12.4 and all of 12.5; Article 16;
Article 18; Article 20; Article 21; Article 24; Sections 25.4(a) and (b);
Article 27; Article 28; Article 31; Article 34; Article 35; Articles 37 & 38;
Article 40; Articles 43 - 46; Sections 47.1 - 47.13, 47.15 - 47.17, 47.20,
Article 48, Article 49 and all exhibits to the Prime Lease.

      (c) The following provisions of the Prime Lease shall be incorporated
herein by reference, but shall be modified as indicated:

            (i) The definition of "Commencement Date" set forth in the Prime
Lease shall be deleted in its entirety and replaced with the definition of
"Commencement Date" set forth above in this Sublease.

            (ii) The definition of "Expiration Date" set forth in the Prime
Lease shall be deleted in its entirety and replaced with the definition of
"Expiration Date" set forth above in this Sublease.

            (iii) The definition of "Fixed Rent" under the Prime Lease shall be
replaced with the definition of "Base Rent" set forth above in this Sublease.

                                       7
<PAGE>

            (iv) The definition of "Term" under the Prime Lease shall be
modified to mean the term of this Sublease as described above in this Sublease.

      (d) To the extent any term or condition of this Sublease conflicts with
any term or condition of the Prime Lease, as between Sublessor and Sublessee
(but not as to Landlord), this sublease shall govern.

      (e) Any and all representations and warranties of Landlord set forth in
the Prime Lease shall be deemed to be representations and/or warranties of
Landlord and shall not be deemed to be representations and/or warranties of
Sublessor and Sublessee shall look solely to Landlord in connection with any
breach and/or enforcement thereof.

      (f) All provisions of the Prime Lease that require Sublessor, as tenant,
to submit, exhibit, supply or provide to Landlord, as lessor, evidence,
certificates, or any other matter or thing shall be deemed to require Sublessee
to submit, exhibit, supply or provide the same to both Landlord and Sublessor.
Sublessee shall submit, exhibit, supply or provide the same to Sublessor and
Sublessor shall submit the same to Landlord, provided however that the submittal
to Landlord of any such materials by Sublessor shall not be deemed consent to
any request for approval by Sublessee. In no event shall Sublessee make any
direct submissions or requests or provide any documentation or materials
directly to Landlord.

      (g) Whenever the approval or consent of Landlord is required under any
provision of the Prime Lease or this Sublease, Sublessee shall be required to
obtain the written approval or consent of Sublessor, and Sublessor shall forward
any request for consent and thereafter use commercially reasonable efforts to
obtain like approval or consent of Landlord. Whenever Sublessor has agreed that
a required approval or consent shall not be unreasonably withheld or delayed it
shall be deemed reasonable for Sublessor to withhold or delay its approval or
consent if Landlord shall have delayed or refused to give any approval or
consent that may be requested of if related to the same matter. Sublessor shall
have no liability for any failure or refusal on the part of Landlord to grant
any such approval or consent. Nothing contained herein shall require Sublessor
to grant its approval or consent merely because Landlord has granted it approval
or consent.

12. SUBLESSEE'S DEFAULT/INDEMNIFICATION AND SUBLESSOR'S REMEDIES.

      (a) An "Event of Default," or default by Sublessee as used in this
Sublease, shall mean (i) any default by Sublessee under any term, covenant or
condition of this Sublease (including, without limitation, any provision of the
Prime Lease incorporated herein by reference) and which default shall have been
continued beyond applicable cure periods provided in this Sublease, (ii) any
default of tenant under the Prime Lease, if the same is caused by an act of
default of Sublessee, (iii) default in the payment of Base Rent or additional
rent within three (3) days after Sublessor's notice to Sublessee that same is
due; (iv) Sublessee's failure to perform any other non-monetary provision of
this Sublease within thirty (30) days (or immediately if the failure involves a
hazardous condition or may cause a default or forfeiture under the Prime Lease
or may cause a violation of Law) after notice from Sublessor; (v) Sublessee's
failure to restore or increase the Security Deposit as required in Section 25
herein;

                                       8
<PAGE>
 (vi) Sublessee's abandonment or vacatur of the Subleased Premises (which shall
be conclusively presumed if the Subleased Premises remains unoccupied for more
than 10 consecutive days); (vii) any voluntary or involuntary proceedings are
filed by or against Sublessee under any bankruptcy, insolvency or similar laws
and, in the case of any involuntary proceedings, are not dismissed within thirty
(30) days after filing or (viii) Sublessee's failure or inability to, or
admitting in writing of its inability to, pay its debts as they become due.

      (b) If Sublessee shall be in default of any term, covenant or condition of
this Sublease, Sublessor shall have available to it all of the remedies
available to Landlord under the Prime Lease in the event of a like default on
the part of the tenant thereunder. The mention in the Prime Lease or this
Sublease of any particular right or remedy shall not preclude Sublessor from
exercising any and all other rights and remedies available to it hereunder at
law and in equity or pursuant to the terms of this Sublease. Upon an occurrence
of any default or Event of Default by Sublessee, Sublessor shall also have the
following rights and remedies, any one of which may be pursued successively or
cumulatively as Sublessor may elect: (i) accelerate all Base Rent, additional
rent and other sums due or to become due hereunder, which shall thereupon be
immediately due and payable in full and (ii) Sublessor may terminate the right
of Sublessee to possession of the Subleased Premises without terminating this
Sublease by giving notice thereof to Sublessee and Sublessor may remove all
occupants and property from the Subleased Premises, using such force as may be
necessary to the extent allowed by laws, without being guilty of in any manner
of trespass, eviction or forcible entry and without relinquishing Sublessor's
right to Base Rent or any additional rent or any other right given to Sublessor
hereunder or by operation of law or in equity. Notwithstanding anything to the
contrary herein or in the Prime Lease, Sublessor shall not have any obligation
to relet the Subleased Premises or otherwise mitigate its damages in the event
of a default by Sublessee.

      (c) Sublessee shall indemnify, defend and hold harmless Sublessor from and
against all claims, liabilities, damages, losses, costs and expenses (including
reasonable attorneys' fees and disbursements) attributable to any damages that
Landlord shall seek to recover from Sublessor attributable to a default by
Sublessee under the terms of this Sublease and Sublessee shall also indemnify,
defend and hold Sublessor harmless from and against all claims, damages,
liabilities, losses, costs, expenses (including, without limitation, reasonable
attorney's fees and disbursements) which Sublessor incurs due to a failure by
Sublessee to comply with any obligation of Sublessee under this Sublease or
which arises from the use or occupancy of the Subleased Premises or any business
conducted therein or any accident or occurrence therein or from any work or
thing whatsoever done by or any condition created by or any other act or
omission of Sublessee.

      (d) In addition, Sublessee shall not do, or permit to be done by any party
for whom Sublessee is legally responsible, any act or thing in or with respect
to the Subleased Premises which will constitute a default under, or violation
of, any of the terms, covenants or conditions of the Prime Lease which pertain
to the Subleased Premises. Sublessee shall indemnify, defend and hold Sublessor
harmless from and against all claims, losses, costs, expenses (including
attorneys' fees and disbursements), damages and liability which Sublessor incurs
due to a failure by Sublessee to comply (after the expiration of all applicable
notice and cure periods)

                                       9
<PAGE>

with any obligation of Sublessee under this Sublease which would constitute a
default or under, or violation of, the Prime Lease.

      (e) Sublessor shall not take any action or fail to take any action which
would be an Event of Default under the Prime Lease, provided the same does not
arise out of or is a result of any action or failure to act by Sublessee.
Sublessor shall indemnify, defend and hold Sublessee harmless from and against
all claims, losses, costs, expenses (including reasonable attorneys' fees and
disbursements), damages and liability which Sublessee incurs due to (i) any
breach or nonperformance of any term contained in this Sublease or the Prime
Lease on the part of Sublessor to be observed, provided the same is not due to
negligence of Sublessee or a breach or failure by Sublessee (or anyone acting by
or through Sublessee) to perform under the terms of this Sublease and (ii) any
injury to persons in or about the Subleased Premises and caused by or resulting
from the fault of Sublessor, its agents, employees, contractors or visitors. The
provisions of Sections 12 (c), (d) and (e) hereunder shall survive the
expiration or earlier termination of this Sublease.

13. LIABILITY INSURANCE.

      (a) Sublessee agrees that during the Term it shall obtain and keep in
force the insurance policies required of Sublessor as tenant under Sections
8.4(b) -8.5 of the Prime Lease and such other insurance as Sublessor may from
time to time reasonably require that Sublessee maintain and all such policies
shall include the Sublessee, as insured, and Sublessor and Landlord, as
additional insureds.

      (b) Sublessee shall furnish a certificate of insurance evidencing all of
the above-described insurance policies prior to or upon execution of this
Sublease and annually, no later than ten (10) business days after the expiration
of each policy. All policies shall provide that no less than thirty (30) days
prior written notice of cancellation, or non-renewal shall be given to the other
party.

14. RESTRICTION ON ASSIGNMENTS, ETC.

      (a) Sublessee shall not assign, mortgage, pledge, encumber, or otherwise
transfer this Sublease, whether by operation of law or otherwise, and shall not
sub-sublet (or underlet), or permit or suffer the Subleased Premises or any part
thereof to be used or occupied by others (whether for desk space, mailing
privileges or otherwise), without Sublessor's prior consent in each instance
which may be withheld in Sublessor's sole discretion. Any assignment,
sub-sublease, mortgage, pledge, encumbrance or transfer in contravention of the
provisions of this Section 14 shall (i) constitute an Event of Default under
this Sublease and (ii) be null and void.

      (b) If Sublessee is a corporation, the transfer by one or more transfers,
directly or indirectly, by operation of law or otherwise, of a majority of the
stock of Sublessee shall be deemed a voluntary assignment of this Sublease;
provided, however, that the provisions of this Section 14(f) shall not apply to
the transfer of shares of stock of Sublessee if and so long as Sublessee is
publicly traded on a nationally recognized stock exchange. For purposes of this
Section the term "transfers" shall be deemed to include the issuance of new
stock or of treasury

                                       10
<PAGE>

stock which results in a majority of the stock of Sublessee being held by a
Person or Persons, that do not hold a majority of the stock of Sublessee on the
date hereof. If Sublessee is a partnership, the transfer by one or more
transfers, directly or indirectly, by operation of law or otherwise, of a
majority interest in the partnership shall be deemed a voluntary assignment of
this Sublease. If Sublessee is a limited liability company, trust, or any other
legal entity (including a corporation or partnership), the transfer by one or
more transfers, directly or indirectly, of Control of such entity, however
characterized, shall be deemed a voluntary assignment of this Lease.

      (c) Notwithstanding anything to the contrary herein and provided the same
is permitted pursuant to the terms of the Prime Lease, Sublessee shall have the
right, without Sublessor's consent but upon thirty (30) days prior notice, to
assign this Sublease to a successor entity by merger or acquisition provided
that (i) the nature of the business and the proposed use of the Subleased
Premises shall be the same as the Permitted Use, and (ii) the net worth of the
successor entity shall be equal to or greater than Sublessee's net worth on the
date of this Sublease. No assignment shall be binding on Sublessor unless such
assignee shall deliver to Sublessor an instrument containing a covenant of
assumption by such assignee. Notwithstanding the foregoing, such assignment must
not have been entered into, in whole or in part, as a subterfuge to avoid the
obligations and restrictions set forth in this Sublease and no assignment shall
act to release Sublessee from its obligations under this Sublease.

15. ALTERATIONS.

The following provisions regarding alterations shall supplement and be in
addition to the provisions of the Prime Lease regarding alterations:

      (a) (i) SUBLESSEE'S ALTERATIONS. Sublessee shall not make any alterations,
additions or other physical changes in or about the Subleased Premises, or other
alterations to prepare the Subleased Premises for its use (collectively,
"ALTERATIONS"), other than decorative Alterations such as painting, wall
coverings and floor coverings (collectively, "DECORATIVE ALTERATIONS"), without
Sublessor's (and if required by the Prime Lease, Landlord's) prior consent,
which may be withheld in Sublessor's and/or Landlord's sole discretion.
Sublessor will not unreasonably withhold its consent to Alterations so long as
such Alterations (i) are non-structural and do not affect the building
systems, (ii) are performed by contractors approved by Sublessor and/or Landlord
to perform such Alterations, (iii) affect only the Subleased Premises and are
not visible from outside of the Subleased Premises or the Building, (iv) do not
affect the certificate of occupancy issued for the Building or the Subleased
Premises, (v) are consistent with the design, construction and equipment of the
Building, (vi) do not adversely affect any service furnished by Landlord or
Sublessor in connection with the operation of the Building, (vii) are in
compliance with all the terms of the Prime Lease and (viii) are consented to by
Landlord pursuant to the terms of the Prime Lease. Notwithstanding anything to
the contrary herein, all alterations by Sublessee shall be architecturally
similar to the existing improvements in the building in Sublessor's reasonable
judgment and all construction materials and laboratory furnishings shall be of
equal or greater quality than those currently existing in the Building and any
fume hoods and biosafety cabinets installed by Sublessee shall be from the same
manufacturer.

                                       11
<PAGE>

            (ii) PLANS AND SPECIFICATIONS. Prior to making any Alterations,
Sublessee, at its expense, shall (i) submit to Sublessor (and if required by the
Prime Lease, to Landlord) for its approval, detailed plans and specifications
(including layout, architectural, mechanical, electrical, plumbing, sprinkler
and structural construction drawings using the AutoCAD Computer Assisted
Drafting and Design System, Version 12 or later of each proposed Alteration
(other than Decorative Alterations), (ii) obtain all permits, approvals and
certificates required by any governmental authorities, (iii) furnish to
Sublessor and to Landlord duplicate original policies or certificates of
insurance (covering all persons to be employed and work to be completed by
Sublessee, and Sublessee's contractors and subcontractors in connection with
such Alteration) evidencing insurance policies and the terms as required in
Section 13, and (iv) furnish to Sublessor and Landlord such other evidence of
Sublessee's ability to complete and to fully pay for such Alterations (other
than Decorative Alterations), including posting a bond or other security, as is
satisfactory to Sublessor (and if required by the Prime Lease, Landlord).
Sublessee shall give Sublessor and Landlord (as required) not less than five (5)
Business Days' notice prior to performing any Decorative Alteration, which
notice shall contain a description of such Decorative Alteration.

            (iii) GOVERNMENTAL APPROVALS; PLANS. Upon completion of any
Alterations, Sublessee, at its expense, shall promptly obtain certificates of
final approval of such Alterations required by any Governmental Authority, and
shall furnish Sublessor and Landlord with copies thereof, together with
"as-built" plans and specifications for such Alterations (other than Decorative
Alterations) prepared on the AutoCAD Computer Assisted Drafting and Design
Systems Version 12 or later (or such other system or medium as Sublessor and
Landlord may accept), using naming conventions issued by the American Institute
of Architects in June, 1990 (or such other naming convention as Sublessor and
Landlord may accept) and magnetic computer media of such record drawings and
specifications, translated into DXF format or another format acceptable to
Sublessor and Landlord.

      (b) MANNER AND QUALITY OF ALTERATIONS. All Alterations shall be performed
(i) in a good and workmanlike manner and free from defects, (ii) in accordance
with the plans and specifications as required under paragraph (a) above, and by
contractors, approved by Sublessor and Landlord, (iii) under the supervision of
a licensed architect reasonably satisfactory to Sublessor and Landlord (other
than Decorative Alterations), and (iv) in compliance with all in compliance with
all applicable Laws, the terms of this Sublease, all procedures and regulations
then prescribed by Landlord for work performed in the Building. All materials
and equipment to be used in the Subleased Premises shall be of equal or greater
quality than those currently existing in the Building as of the date of this
Sublease, and no such materials or equipment shall be subject to any lien or
other encumbrance.

      (c) REMOVAL OF SUBLESSEE'S PROPERTY. All Building Standard Alterations (as
defined in this Section) shall be the property of Sublessor and/or Landlord and
shall not be removed by Sublessee without the prior approval of Sublessor. All
Above Building Standard Alterations (as defined in this Section) and Sublessee's
property shall be and, except as hereinafter provided, shall remain the property
of Sublessee. On or prior to the Expiration Date or sooner termination of the
Term, Sublessee shall, at Sublessee's expense, remove all of Sublessee's
property and, unless otherwise directed by Sublessor and/or Landlord: (i) close
up any slab penetrations in the

                                       12
<PAGE>

Premises and (ii) remove any Alterations which (x) Sublessor is required to
remove pursuant to the Prime Lease, (y) Sublessor advised Sublessee it must
remove at the time of approval of Sublessee's plans for such Alterations and/or
(z) are Above Building Standard Alterations (but nothing herein shall give
Sublessee a right to make any such alterations, additions and improvements). At
least sixty (60) days prior to commencing the removal of any Alterations
(including without limitations those specified in the preceding sentence) or the
closing of any slab penetrations, Sublessee shall notify Sublessor of its
intention to remove such Alterations or effect such closings, and if Sublessor
and/or Landlord notifies Sublessee within such sixty (60) day period, Sublessee
shall not remove such Alterations or close such slab penetrations, and the
Alterations not so removed shall become the property of Sublessor and/or
Landlord upon the Expiration Date or sooner termination of the Term. Sublessee
shall repair and restore, in a good and workmanlike manner, any damage to the
Subleased Premises and/or the Building caused by Sublessee's removal of any
Alterations or Sublessee's property, or by the closing of any slab penetrations,
and if Sublessee fails to do so, Sublessee shall reimburse Sublessor and/or
Landlord, on demand, for Sublessor's and/or Landlord's cost of repairing and
restoring such damage. Any Above Building Standard Alterations or Sublessee's
property not removed on or before the Expiration Date or sooner termination of
the Term shall be deemed abandoned (unless Sublessor previously advised
Sublessee that it shall not so remove such Above Building Standard Alterations)
and Sublessor may either retain the same as Sublessor's property or remove and
dispose of same, and repair and restore any damage caused thereby, at
Sublessee's cost and without accountability to Sublessee. For the purposes of
this Sublease, (x) Alterations and improvements, the cost of which generally
conform to the cost of improvements typically performed in connection with the
initial occupancy of tenants in the Building for office and laboratory use are
defined as "BUILDING STANDARD ALTERATIONS", and (y) Alterations or improvements
which exceed Building Standard Alterations are defined as "ABOVE BUILDING
STANDARD ALTERATIONS". Notwithstanding anything to the contrary herein,
Sublessee shall not remove any laboratory benches or fume hoods from the
Subleased Premises whether currently existing on the Subleased Premises or
installed after the Commencement Date and all improvements made to the
Unfinished Space by Sublessee which are standard laboratory improvements shall
be deemed Building Standard Alterations and shall not be removed by Sublessee
unless Sublessor so advised Sublessee prior to the expiration of the Term that
Sublessee shall remove the same.

      (d) MECHANIC'S LIENS. Sublessee, at its expense, shall discharge any lien
or charge filed against the Subleased Premises, the Building or the Real
Property in connection with any work claimed or determined in good faith by
Sublessor and/or Landlord to have been done by or on behalf of, or materials
claimed or determined in good faith by Sublessor and/or Landlord to save been
furnished to, Sublessee, within twenty (20) days after Sublessee's receipt of
notice thereof by payment, filing the bond required by law or otherwise in
accordance with law.

      (e) LABOR RELATIONS. Sublessee shall not employ, or permit the employment
of, any contractor or laborer, or permit any materials to be delivered to or
used in the Building, if, in Sublessor's and/or Landlord's sole judgment, such
employment, delivery or use will interfere or cause any conflict or disharmony
with other contractors or laborers engaged in the construction, maintenance or
operation of the Building by Landlord, Sublessee or others, or the use and
enjoyment of the Building by other tenants or occupants. In the event of such
interference,

                                       13
<PAGE>

conflict or disharmony, upon Sublessor's and/or Landlord's request, Sublessee
shall cause all contractors or laborers causing such interference or conflict to
leave the Building immediately.

      (f) SUBLESSEE'S COSTS. To the extent that any fees (administrative or
otherwise) are due Landlord in connection with any Alterations made by Sublessee
in the Subleased Premises (including the Initial Installations), Sublessee shall
pay to Sublessor, within ten (10) days after demand, all out-of-pocket costs
incurred by Sublessor in connection therewith, including, but not limited to,
costs incurred in connection with (i) review of the Alterations (including
review of requests for approval thereof), and (ii) the provision of Building
personnel during the performance of any Alterations required by trade union
policy or otherwise, to operate elevators or otherwise to facilitate Sublessee's
Alterations.

      (g) SUBLESSEE'S EQUIPMENT. Sublessee shall not move any heavy machinery,
heavy equipment, freight, bulky matter or fixtures into or out of the Building
without Sublessor's and/or Landlord's prior consent and payment to Sublessor or
Landlord of Landlord's reasonable charges in connection therewith. If any such
machinery, equipment or other items require special handling, Sublessee agrees
(i) to employ only persons holding a Master Rigger's License to perform such
work, and (ii)such work shall be done only during hours designated by Landlord.

      (h) LEGAL COMPLIANCE. The approval of plans or specifications, or the
consent by Sublessor and/or Landlord to the making of any Alterations, does not
constitute Sublessor's and/or Landlord's agreement or representation that such
plans, specifications or Alterations comply with any Laws or the certificate of
occupancy issued for the Building. Neither Sublessor nor Landlord shall have any
liability to Sublessee or any other party in connection with Sublessor's and/or
Landlord's approval of plans and specifications for any Alterations, or
Sublessor's and/or Landlord's consent to Sublessee's performing any Alterations.
If, as the result of any Alterations made by or on behalf of Sublessee,
Sublessor and/or Landlord is required to make any alterations or improvements to
any part of the Building in order to comply with any Laws, whether or not in the
Subleased Premises, Sublessee shall pay all costs and expenses incurred by
Sublessor and/or Landlord in connection with such alterations or improvements.

      (i) LANDLORD'S RIGHT OF CONSTRUCTION. Notwithstanding anything to the
contrary herein, Sublessee shall comply with the provisions of Section 3.12 of
the Prime Lease with respect to any alterations or improvements to the
Unfinished Space and shall afford Landlord its construction right of first
refusal as provided therein.

      (j) SUBLESSEE CONSTRUCTION OF THE UNFINISHED SPACE. Sublessor acknowledges
that Sublessee is to build-out the Unfinished Space pursuant to the terms of
Section 7 of this Sublease (the "UNFINISHED SPACE ALTERATIONS") and that the
Unfinished Space Alterations may affect the building systems and structure of
the Building. Notwithstanding anything to the contrary herein, Sublessor will
not unreasonably withhold its consent to the Unfinished Space Alterations
provided (i) Landlord consents to the Unfinished Space Alterations, (ii) such
alterations do not adversely affect building systems or the structural integrity
of the building and (iii) such alterations otherwise comply with the provisions
of this Section 15.

                                       14
<PAGE>
     (k) ENTRANCE APPEARANCE. Notwithstanding anything to the contrary in this
Sublease, Sublessee shall not make any Alterations that may change the
appearance of the space visible from the main lobby area without Sublessor's
consent which may be withheld in Sublessor's sole discretion, it being
understood that this space shall remain a first-class office/reception area at
all times during the Term.

16.  REPAIRS

     (a) Sublessee shall make all repairs or replacements that Sublessor is
required to make under the Prime Lease with respect to the Subleased Premises.
To the extent Landlord makes any repair or replacement with respect to the
Subleased Premises for which Sublessor is required to pay for all or any of the
cost thereof, Sublessee shall, within thirty (30) days after rendition of a bill
thereof by Sublessor from time to time, pay Sublessor for any such cost for
which Sublessor is liable.

     (b) Sublessor reserves the right to make any and all changes, alterations,
additions, improvements, repairs or replacements to any and all pipes, wires,
cables, ducts, conduits and other equipment used by Sublessor to provide to
Sublessee any of the services provided by Sublessor to Sublessee pursuant to
this Sublease, as Sublessor deems necessary or desirable, provided that in no
event shall the level of any such service decrease in any material respect from
the level required of Sublessor in this Sublease as a result thereof (other than
temporary changes in the level of such services during the performance of any
such work by Sublessor). Sublessor shall use reasonable efforts to minimize
interference with Sublessee's use and occupancy of the Subleased Premises during
the making of such changes, alterations, additions, improvements, repairs or
replacements, provided that Sublessor shall have no obligation to employ
contractors or labor at overtime or other premium pay rates or to incur any
other overtime costs or additional expenses whatsoever. Except as otherwise
provided herein, there shall be no abatement of Base Rent or any additional rent
or allowance to Sublessee for a diminution of rental value, no actual or
constructive eviction of Sublessee, in whole or in part, no relief from any of
Sublessee's other obligations under this Sublease, and no liability on the part
of Sublessor, by reason of inconvenience, annoyance or injury to business
arising from Landlord, Sublessor, Sublessee or others making, or failing to
make, any repairs, alterations, additions or improvements in or to any portion
of the Building or the Subleased Premises, or in or to fixtures, appurtenances
or equipment therein.

17.  FURNITURE.

     (a) Sublessee shall have the right, without charge by Sublessor therefor,
to use all of the Furniture and telephone desk sets in the Subleased Premises,
provided that Sublessee shall, throughout the term of the Sublease, take good
care of same at Sublessee's sole cost and expense. All damage to the Furniture
and telephone desk sets shall be repaired promptly by Sublessee at its sole cost
and expense. Sublessee shall, at the expiration or earlier termination of the
Sublease term, surrender all Furniture and telephone desk sets to Sublessor in
the condition it was in on the Commencement Date subject, however, to reasonable
wear and tear. Sublessee shall use the Furniture in a reasonable manner and only
for the uses for which it was intended.

                                       15
<PAGE>

Sublessee accepts all risks with respect to the Furniture and Sublessor shall
not be liable for any damage or loss caused by or attributable to the Furniture.

     (b) Notwithstanding anything to the contrary in this Sublease, Sublessee
shall obtain and use its own telephone switch (PBX equipment) and
telecommunications services, at its sole cost and expense.

     (c) Sublessor shall disconnect the existing data/voice wiring from the main
point of demarcation in the Subleased Premises on or prior to the Commencement
Date. Sublessee shall reterminate and redirect such wiring within the Subleased
Premises at Sublessee's sole cost and expense.

18.  SERVICES/NON-LIABILITY OF SUBLESSOR/RENT ABATEMENT.

     (a) Sublessor shall have no obligation to comply with any laws, perform any
work, or provide any services or make any repairs in or to the Subleased
Premises whatsoever or to maintain any insurance or to perform any other
obligation which is the obligation of Landlord under the Prime Lease. Sublessee
recognizes that all services and repair obligations other than those to be
provided by Sublessor pursuant to Sections 18(b) and (c) and Section 32, to
which Sublessee is entitled under this Sublease are to be supplied by Landlord
under the Prime Lease and not by Sublessor. In the event that Landlord shall
fail to perform such services and/or repair obligations or shall refuse to
comply with any of the provisions of the Prime Lease insofar as they materially
affect Sublessee's occupancy of the Subleased Premises, Sublessor shall, at the
written request of Sublessee, use commercially reasonable, good faith efforts to
cause Landlord to so comply but without any obligation to incur any cost,
expense, liability or obligation whatsoever. Sublessor shall be under no
liability to Sublessee in the event of the failure by Landlord to supply any
services, unless the same is due to the wrongful act or the wrongful failure to
act (where action is required hereunder) of Sublessor.

     (b) Sublessor shall provide (1) standard heating and air-conditioning
("HVAC") service to the (x) Office Premises from 7 A.M. to 7 P.M. on Business
Days, (y) Lab Space 24 hours per day provided that night temperature set-back
shall be provided after 7 PM and on non- Business Days, (z) Unfinished Space in
the same manner provided to the Lab Space upon Sublessee's completion of the
Alterations to the Unfinished Space in accordance with plans approved by
Sublessor therefor; (2) Uninterruptible Power Supply and emergency power
(collectively the "EMERGENCY POWER") to the Subleased Premises provided that no
Event of Default has occurred and to the extent that it currently exists within
the Subleased Premises (i.e. Sublessee shall have the right, upon approval of
plans therefor by Sublessor, to connect to the existing panels for the Emergency
Power, but shall not create any new panels for such service); (3) hot and cold
water to the Subleased Premises for ordinary office and bathroom use; (4)
natural gas to the Lab Space and Unfinished Space for ordinary laboratory use;
(5) deionized water to the Lab Space and Unfinished Space for ordinary
laboratory use and (6) ordinary laboratory vacuum system ("VACUUM SYSTEM") to
the Lab Space and Unfinished Space for ordinary laboratory use.

                                       16
<PAGE>

     (c) Sublessor shall maintain, repair and replace, if necessary the HVAC
system, Vacuum System, fire alarm and elevator servicing the Subleased Premises
and shall maintain the common areas of the interior of the Building, at
Sublessor's expense (as part of the Fixed Operating Expense Charge) unless any
repairs, maintenance or replacements are due to Sublessee's negligence or
Sublessee's alterations in which case Sublessee shall pay, as additional rent,
Sublessor's cost and expense for such repair or maintenance or replacement.
Notwithstanding anything to the contrary herein, Sublessor shall not be
obligated to upgrade or make any additions to the HVAC system, Emergency Power
or Vacuum System and Sublessee shall only use such systems within their design
specifications. Sublessee shall also use the Vacuum System with traps and other
protection devices so as to prevent the contamination of the Vacuum System
piping and equipment with any chemical. If contamination of the Vacuum System
occurs, Sublessee shall promptly decontaminate same or replace the component of
the system contaminated at Sublessee's sole cost and expense (or shall pay the
cost thereof to Sublessor if Sublessor elects, in its sole discretion, to
perform such decontamination and/or replacement), and Sublessor reserves the
right, in addition to any other rights or remedies Sublessor may have, to
discontinue providing the Vacuum System or any other service provided to
Sublessee if Sublessee fails to use such systems or services in the manner
described herein.

     (d) Sublessor shall not be liable in any way to Sublessee for any failure,
defect or interruption of any service, utility or other system to be supplied by
Sublessor, including without limitation the Emergency Power, except if
attributable to the gross negligence or willful misconduct of Sublessor, nor
(except as otherwise provided in this Sublease) shall there be any allowance to
Sublessee or diminution of rental value, nor shall the same constitute an actual
or constructive eviction of Sublessee, in whole or in part, or relieve Sublessee
of from any of its Sublease obligations. In addition, in no event (either
through indemnity or otherwise) shall Sublessor be liable to Sublessee for any
consequential, punitive or other damages.

     (e) Sublessee shall provide all cleaning and janitorial services to the
Subleased Premises, including but not limited to the removal of biohazardous
waste as referred to in Section 34 of this Sublease, at Sublessee's sole costs
and expense, to the reasonable satisfaction of Sublessor. Sublessee shall keep
its Premises clean and use the same cleaning service utilized by the Sublessor
to clean the Building unless otherwise approved in writing by Sublessor. In
addition, Sublessee shall make any non-structural repairs to the Subleased
Premises and the fixtures and appurtenances therein as and when needed to
preserve the Subleased Premises in good order and condition, except for
reasonable wear and tear.

     (f) Notwithstanding anything to the contrary in this Sublease, in the event
that Sublessee is unable to use all or more than 20% of the Subleased Premises
for the ordinary conduct of its business as a result solely of (x) Sublessor's
breach of an obligation under this Sublease to perform repairs or provide
services or (y) disruption in any required services to the Subleased Premises
due solely to Sublessor's negligence or willful misconduct, in each case other
than as result of (i) a fire or other casualty, (ii) breach of this Sublease by
Sublessee or any action or inaction by Sublessee, (iii) breach of the Prime
Lease by Landlord or any action or inaction by Landlord or (iv) any other cause
not within Sublessor's control, and such condition continues for a period in
excess of ten (10) consecutive Business Days after the date of notice from
Sublessee to Sublessor (the "ABATEMENT NOTICE") stating Sublessee's inability to
use all or

                                       17
<PAGE>

more than 20% percent of the Subleased Premises, then, provided Sublessee
vacates and does not use all or such portion of the Subleased Premises, the Base
Rent shall be abated on a per diem basis and in proportion to the portion of the
Subleased Premises not used by Sublessee for the period commencing on the
eleventh (11th) day after Sublessor receives the Abatement Notice, and ending
on the earlier of the date on which (A) Sublessee reoccupies all or a portion of
the Subleased Premises for the ordinary conduct of its business, or (B) such
condition is substantially remedied.

19.  NOTICES

Subject to the provisions of Section 5 hereof, any notice, demand, bill,
invoice, statement or communication which either Sublessor or Sublessee may
desire or be required to give to the other in connection with this Sublease
shall be in writing and shall be deemed to have been sufficiently given or
rendered if delivered by hand (against a signed receipt), or by reputable
overnight courier service (against a signed receipt), or by registered or
certified mail (return receipt requested), to such other party at the following
addresses:

           To Sublessor:      Purdue Pharma, L.P.
                              One Stamford Forum
                              Stamford, CT 06901
                              Attention: Diana Lenkowsky

                              copy to:

                              Herrick, Feinstein, LLP
                              2 Penm Plaza
                              Newark, NJ 07105
                              Attention: Joann B. Birle, Esq.

           To Sublessee:

                Before Sublessee commences business in the Subleased Premises:

                              Amicus Therapeutics, Inc.
                              675 U.S. Highway One
                              North Brunswick, NJ 08902
                              Attention: Ms. Allison Sorokin

                After Sublessee commences business in the Subleased Premises
                at the Subleased Premises:

                              Amicus Therapeautics, Inc.
                              6 Cedar Brook Drive
                              Cranbury, NJ 08512
                              Attention: Ms. Allison Sorokin

                                       18
<PAGE>

                              copy to:

                              Riker, Danzig, Scherer, Hyland & Peretti LLP
                              One Speedwell Avenue
                              Morristown, NJ 079625
                              Attention: Nicholas Racioppi, Jr., Esq.

           To Landlord:       Cedar Brook 10 Corporate Center, L.P.
                              1000 Eastpark Blvd.
                              Cranbury, NJ 08512

                              with a copy to:

                              Stephen J. Edwards, Esq.
                              59 Forrest Road
                              Randolph, NJ 07869

or to such other address(es) as Sublessor or Sublessee (or Landlord, if
applicable) may designate as its new address(es) for such purpose by notice
given to the parties in accordance with the provisions of this Section 19. Any
such bill, invoice, statement, notice or communication shall be deemed to have
been rendered or given on the date when it shall have been delivered (as
evidenced by a signed receipt, or, as the case may be, the date of delivery
shown on the return receipt) or upon refusal to accept delivery. Counsel for
Sublessor and Sublessee may deliver notices on behalf of their respective
clients in connection with this Sublease.

20.  TIME LIMITS.

The time limits set forth in the Prime Lease for the performance of any act or
the making of any payment are, for the purposes of this Sublease, changed so
that the time of Sublessee in a particular case hereunder to do or perform any
act or make any payment shall be three (3) days less than the time of Sublessor
as tenant under the Prime Lease to do so in such case (taking into account the
maximum grace period, if any, relating thereto contained in the Prime Lease).
Each party shall promptly deliver to the other party copies of all notices,
requests or demands which relate to the Subleased Premises or the use or
occupancy thereof after receipt of same from Landlord.

21.  BROKERAGE.

Sublessor and Sublessee warrant and represent to each other that in connection
with this Sublease, they have dealt with no brokers except Triad Properties,
Inc., ("TRIAD") Calloway Commercial ("CALLOWAY") and Cushman and Wakefield of
New Jersey ("CW") (collectively, the "BROKER"). Sublessor and Sublessee shall
indemnify, defend and hold the other harmless (including the payment of
attorney's fees) from any claim of any broker that Sublessor or Sublessee had,
or is alleged to have had, dealings with concerning this Sublease other than the
Broker Sublessor shall pay Triad and CW any amounts to which Broker is entitled
in connection with this Sublease, pursuant to a separate written agreement, and
Triad shall pay to

                                       19
<PAGE>

Calloway any amounts to which Calloway is entitled in connection with this
Sublease, pursuant to a separate written agreement.

22.  SURRENDER OF SUBLEASED PREMISES; HOLDING OVER.

     (a) Sublessor and Sublessee recognize that the damage to Sublessor
resulting from any failure by Sublessee to timely surrender possession of the
Subleased Premises may be substantial, may exceed the amount of the Base Rent
and additional rent theretofore payable hereunder, and will be impossible to
accurately measure. Sublessee therefore agrees that if possession of the
Subleased Premises is not surrendered to Sublessor on or before the Expiration
Date, in addition to any other rights or remedies Sublessor may have hereunder
or at law or in equity, Sublessee shall:

          (i) pay to Sublessor for each month (or any portion thereof) during
which Sublessee holds over in the Subleased Premises after the Expiration Date,
a sum equal to the greater of (i) two times (2x) the aggregate of the Base Rent
(as defined in the Prime Lease) and additional rent payable under the Prime
Lease for the last full calendar month of the term thereunder, or (ii) two times
(2x) the fair market rental value of the Subleased Premises for such month (as
reasonably determined by Sublessor);

          (ii) be liable to Sublessor for (A) any payment or rent concession
which Sublessor may be required to make to any sublessee obtained by Sublessor
for all or any part of the Subleased Premises (a "NEW SUBLESSEE") in order to
induce such New Sublessee not to terminate its lease by reason of the
holding-over by Sublessee, and (B) the loss of the benefit of the bargain if any
New Sublessee shall terminate its lease by reason of the holding-over by
Sublessee;

          (iii) be liable to Sublessor for, and indemnify, defend and hold
Sublessor harmless from and against, any and all claims, actions, and suits by
any New Sublessee and any and all costs, expenses (including attorneys' fees and
expenses), losses, damages, liabilities, and obligations Sublessor may incur in
connection therewith; and

          (iv) be liable to Sublessor for, and indemnify, defend and hold
Sublessor harmless from and against, any and all claims, actions, suits, costs,
expenses (including attorneys' fees and expenses), losses, damages, liabilities,
and obligations Sublessor may incur under or in connection with the Prime Lease
by reason of the holding-over by Sublessee.

     (b) No holding-over by Sublessee, nor the payment to Sublessor of the
amounts specified above, shall operate to extend the Term hereof. Nothing herein
contained shall be deemed to permit Sublessee to retain possession of the
Premises after the Expiration Date, and no acceptance by Sublessor of payments
from Sublessee after the Expiration Date shall be deemed to be other than on
account of the amount to be paid by Sublessee in accordance with the provisions
of this Section. If Sublessee does hold over, Sublessor may exercise any and all
rights under this Sublease and/or as may exist at law and/or in equity
(including, without limitation, resort to summary proceedings) to obtain
possession of the Subleased Premises.

                                       20
<PAGE>

     (c) The obligations of Sublessee under this Section 22 shall survive the
expiration or termination of the Term.

23.  CAPTIONS.

The captions in this Sublease are used for convenience and reference only and
are not to be taken as part of this Sublease or to be used in determining the
intent of the parties or otherwise interpreting this Sublease.

24.  SUCCESSORS AND ASSIGNS.

This Sublease shall be binding upon and inure to the benefit of Sublessor and
Sublessee and their respective successors and permitted assigns.

25.  SECURITY DEPOSIT

     (a) Simultaneously with the execution and delivery of this Sublease,
Sublessee has deposited (the "SECURITY DEPOSIT") with Sublessor the sum of Two
Hundred Sixty-Seven Thousand Three Hundred Thirty-Eight Dollars ($267,338) to be
held during the Term as security for the payment of the Base Rent, additional
rent and all other sums of money payable by Sublessee under this Sublease, and
for the faithful performance of all other covenants and agreements of Sublessee
under this Sublease. The Security Deposit shall be returned to Sublessee
(subject to the application thereof to any unpaid "SECURED OBLIGATION" as
hereinafter defined) within thirty (30) days after the expiration date of this
Sublease. Said Security Deposit be held in a non-segregated, non-interest
bearing account.

     (b) Notwithstanding anything to the contrary set forth herein and subject
to the terms and conditions of this Article 25, if Sublessee fails to commence
construction and/or thereafter diligently continue and complete construction of
the Unfinished Space in accordance with the plans approved therefor by Sublessor
within nine (9) months after the Commencement Date, the Security Deposit shall
be increased on the nine month anniversary of the Commencement Date (the
"SECURITY INCREASE DATE") to Eight Hundred and Two Thousand Thirteen Dollars
($802,013) and such amount shall be deemed to be the Security Deposit hereunder.
The failure by Sublessee to provide such increase in the Security Deposit shall
be deemed to be a material breach of the terms of this Sublease and an Event of
Default.

     (c) If an Event of Default shall occur hereunder, in addition to all of
Sublessor's right and remedies set forth in this Sublease, within ten (10) days
after notice by Sublessor, Sublessee shall immediately restore the Security
Deposit to the full amount of the Security Deposit.

     (d) Sublessee's Federal Identification Number is (omitted).

     (e) If an Event of Default shall occur and be continuing, Sublessor may,
subject to the terms and conditions hereinafter set forth, apply the whole or
any part of the Security Deposit (i) toward the payment of any Base Rent or any
item of additional rent due under this Sublease as to which Sublessee is then in
default beyond any applicable notice, cure and/or grace period and (ii)

                                       21
<PAGE>

toward any sum which Sublessor may expend or may be required to expend by reason
of Sublessee's default, beyond any applicable notice, cure and/or grace period,
in respect of any of the terms, covenants and conditions of this Sublease (the
obligations of Sublessee set forth in the foregoing clauses (i) and (ii) being
referred to collectively herein as the "SECURED OBLIGATIONS"). If Sublessor
applies or retains any part of the proceeds of the Security Deposit, Sublessee,
upon demand by Sublessor, shall deposit with Sublessor the amount so applied or
retained so that Sublessor shall have the full Security Deposit on deposit as
security for the Secured Obligations, at all times during the Term.

     (f) In lieu of the cash security deposit, Sublessee may at any time during
the Term deliver to Sublessor and shall thereafter maintain in effect a clean,
irrevocable, non-documentary and unconditional letter of credit, in the form
attached hereto as EXHIBIT E (the "LETTER OF CREDIT") issued by and drawable
upon any commercial bank, trust company, national banking association or savings
and loan association with offices for banking and drawing purposes in the State
of New Jersey (the "ISSUING BANK"), which has outstanding unsecured, uninsured
and unguaranteed indebtedness, or shall have issued a letter of credit or other
credit facility that constitutes the primary security for any outstanding
indebtedness (which is otherwise uninsured and unguaranteed), that is then
rated, without regard to qualification of such rating by symbols such as "+" or
"-" or numerical notation, "Aa" or better by Moody's Investors Service and "AA"
or better by Standard & Poor's Ratings Service (and is not on credit-watch with
negative implications), and has combined capital, surplus and undivided profits
of not less than $500,000,000. The Letter of Credit shall (i) name Sublessor as
beneficiary, (ii) be in the amount of the Security Deposit, (iii) have a term of
not less than one (1) year, (iv) permit multiple drawings, (v) be fully
transferable by Sublessor multiple times without the consent of Sublessee and
without the payment of any fees or charges, (vi) be payable to Sublessor or an
authorized representative of Sublessor upon presentation of only the Letter of
Credit and a sight draft and shall not contain as a condition to a draw the
requirement of Sublessor's certification or other statement as to the existence
of Sublessee's default, and (vii) otherwise be in form and content satisfactory
to Sublessor. If upon any transfer of the Letter of Credit, any fees or charges
shall be so imposed, then such fees or charges shall be payable solely by
Sublessee and the Letter of Credit shall so specify. The Letter of Credit shall
provide that it shall be deemed automatically renewed, without amendment, for
consecutive periods of one (1) year each thereafter during the Term through the
date that is at least sixty (60) days after the Expiration Date, unless the
Issuing Bank sends a notice (the "NON-RENEWAL NOTICE") to Sublessor by certified
mail, return receipt requested, not less than sixty (60) days prior to the
then-current expiration date of the Letter of Credit, stating that the Issuing
Bank has elected not to renew the Letter of Credit. Sublessor shall have the
right to draw upon the Letter of Credit (in whole or in part, at Sublessor's
discretion) at any time or times that Sublessor shall, under this Sublease, be
entitled to retain or apply all or any portion of the Security Deposit.
Sublessor also shall have the right, upon receipt of a Non-Renewal Notice, to
draw the full amount of the Letter of Credit, by sight draft on the Issuing
Bank, and shall thereafter hold or apply the cash proceeds of the Letter of
Credit pursuant to the terms of this Section 25. The Letter of Credit shall
state that drafts drawn under and in compliance with the terms of the Letter of
Credit will be duly honored upon presentation to the Issuing Bank at an office
location in the State of New Jersey or the State of Connecticut. The Letter of
Credit shall be subject in all respects to the International Standby Practices
1998, International Chamber of Commerce Publication No. 590. Sublessee shall
cooperate, at

                                       22
<PAGE>

Sublessee's expense, with Sublessor to promptly execute and deliver to Sublessor
any and all modifications, amendments, and replacements of the Letter of Credit,
as Sublessor may reasonably request to carry out the intent, terms and
conditions of this Section 25. If Sublessee is required to increase the Security
Deposit as required in this Section 25, Sublessee may tender to Sublessor a
replacement Letter of Credit for such increased amount and thereupon, Sublessor
shall exchange the Letter of Credit it is then holding for such replacement
Letter of Credit. If Sublessor applies or returns any part of the proceeds to
the Security Deposit, Sublessee, upon demand by Sublessor, shall deposit with
Sublessor the amount so applied or retained in the form of an additional letter
of credit meeting the requirements hereof, or an increase in the amount of the
tetter of credit meeting the requirements hereof so that Sublessor shall have
the full Security Deposit on deposit as security for the Secured Obligations, at
all times during the Term.

     (g) Upon an assignment of the Sublease and assumption of the obligations of
Sublessor by the assignee, Sublessor shall have the right to transfer the cash
Security Deposit or the Letter of Credit, as applicable, to the assignee. With
respect to the Letter of Credit, within ten (10) days after notice from
Sublessor of any such anticipated assignment, Sublessee, at its sole cost, shall
arrange for the transfer of the Letter of Credit to the new sublessor, as
designated by Sublessor in the foregoing notice, or to have the Letter of Credit
reissued in the name of the new sublessor. Sublessee shall look solely to the
new sublessor for the return of such cash Security Deposit or Letter of Credit,
and the provisions of this subsection shall apply to every transfer or
assignment made of the Security Deposit to a new sublessor. Sublessee will not
assign or encumber, or attempt to assign or encumber, the cash Security Deposit
or Letter of Credit, and neither Sublessor nor its successors or assigns shall
be bound by any such actual or attempted assignment or encumbrance.

     (h) Any cash proceeds of the Letter of Credit which are not otherwise
applied or retained by Sublessor as provided in this Section 25 shall be
invested in a non-segregated, non-interest bearing account.

     (i) The foregoing notwithstanding, it shall be an Event of Default under
this Sublease if Sublessee delivers such a Letter of Credit and the Issuing Bank
sends a Non-Renewal Notice to Sublessor, or if for any reason the Letter of
Credit is not renewed in a timely manner during the entirety of the Term, or if
for any reason the Letter of Credit is not maintained by Sublessee in full force
and effect, in the amount of the Security Deposit during the entirety of the
Term.

26.  ACCESS.

     (a) Subject to the terms and provisions of this Sublease and the Prime
Lease, Sublessee shall have access to the Subleased Premises 24 hours per day,
every day of the year.

     (b) Sublessee and Sublessor acknowledge that as of the date of this
Sublease, Sublessor provides certain security services to the Building.
Sublessee will comply with all security procedures from time to time implemented
by Sublessor, including, without limitation, requirements that any person
entering the Building sign in and/or present satisfactory identification at the
concierge desk and that deliveries be made to a secured freight entrance.
Nothing herein shall impose any obligation on the part of Sublessor to supply or
to cause to be

                                       23
<PAGE>

supplied such security services, or any other security services. Sublessor shall
maintain, or cause to be maintained the current level of security offered by
Sublessor in the Building including the operation of the current front desk
service in the lobby of the Building.

     (e) Sublessor shall have the right, from time to time, to adopt reasonable
rules and regulations with respect to Sublessor's operation and maintenance of
the Building including, without limitation, rules governing access to the
Building.

27.  INTENTIONALLY OMITTED.

28.  PERFORMANCE OF OBLIGATIONS OF LANDLORD UNDER THE PRIME LEASE/OTHER.

Notwithstanding anything to the contrary in this Sublease, Sublessor and
Sublessee agree as follows:

     (a) Sublessee shall not in any event have any rights in respect of the
Subleased Premises greater than Sublessor's rights to such space under the Prime
Lease.

     (b) Any obligation of Sublessor which is contained in this Sublease
(including, without limitation, any obligation for the providing of services,
performance of repairs, or otherwise) by the incorporation by reference of the
provisions of the Prime Lease may be observed or performed
by Sublessor using commercially reasonable efforts to cause Landlord under the
Prime Lease to observe and/or perform the same, and Sublessor shall have a
reasonable time to use such reasonable efforts to so do; and, notwithstanding
any provision to the contrary, as to obligations contained in this Sublease by
the incorporation by reference of the provisions of the Prime Lease, Sublessor
shall not be required to make any payment or perform any obligation, and
Sublessor shall have no liability to Sublessee for any matter whatsoever, except
for Sublessor's obligation to pay the rent and additional rent due under the
Prime Lease and for Sublessor's obligation to use commercially reasonable
efforts where required by this Sublease, upon request of Sublessee, to cause the
landlord under the Prime Lease to observe and/or perform its obligations under
the Prime Lease.

     (c) Sublessor shall not be responsible for any failure or interruption, for
any reason whatsover, except Sublessor's gross negligence or intentional
wrongful act, of any of the services or facilities that may be appurtenant to or
supplied at the Building by the Landlord under the Prime Lease or otherwise,
and no failure to furnish, or interruption of, any such services or facilities
shall give rise to any (i) abatement, diminution or reduction of Sublessee's
obligations under this Sublease, (ii) constructive eviction, whether in whole or
in part, or (iii) liability on the part of Sublessor.

     (d) Sublessee and Sublessor hereby release the other or anyone claiming by,
through or under the other under this Sublease and the Prime Lease and the
Landlord or anyone claiming by, through or under the Landlord under the Prime
Lease by way of subrogation or otherwise to the extent that Sublessor released
the Landlord under the Prime Lease and/or the Landlord under the Prime Lease was
relieved of liability or responsibility pursuant to the provisions of the Prime
Lease, and Sublessee will cause its insurance carriers to include any clauses or
endorsements in

                                       24
<PAGE>
favor of Sublessor and the Landlord under the Prime Lease which Sublessor is
required to provide pursuant to the provisions of the Prime Lease, or Sections
13 and 15(a)(ii) of this Sublease.

      (e) In any instance when Sublessor's consent or approval is required under
this Sublease, Sublessor's refusal to consent to or approve any matter or thing
shall be deemed reasonable if, inter alia, such consent or approval has not been
obtained from the Landlord under the Prime Lease. In the event that Sublessee
shall seek the approval by or consent of Sublessor and Sublessor shall fail or
refuse to give such consent or approval, Sublessee shall not be entitled to any
damages for any withholding or delay of such approval or consent by Sublessor,
it being intended that Sublessee's sole remedy shall be an action for injunction
or specific performance and that said remedy of an action for injunction or
specific performance shall be available only in those cases where Sublessor
shall have expressly agreed in writing not to unreasonably withhold or delay its
consent.

      (f) If for any reason whatsoever the term of the Prime Lease shall
terminate prior to the expiration date of this Sublease, this Sublease shall
thereupon be terminated and Sublessor shall not be liable to Sublessee by reason
thereof. Upon such termination, the obligations of Sublessor and Sublessee
(other than the obligation of Sublessee for the payment of any monies then owing
to Sublessor and such other obligations that are expressly made to be effective
upon the termination of this Sublease as are set forth in the Lease and
incorporated herein by reference and/or as are set forth in this Sublease) shall
cease, except that the parties shall remain liable for any obligations incurred
prior to any such termination date for any matter occurring prior to such date.

      (g) If Sublessee shall at any time fail to make any payment or perform any
other obligation of Sublessee hereunder, then Sublessor shall have the right,
but not the obligation, after three (3) days' notice to Sublessee, or without
notice to Sublessee in the case of any emergency or if such failure would be a
default under the Prime Lease, and without waiving or releasing Sublessee from
any obligations of Sublessee hereunder, to make such payment or perform such
other obligation of Sublessee in such manner and to such extent as Sublessor
shall deem necessary, and in exercising any such right, to pay any incidental
costs and expenses, employ attorneys, and incur and pay reasonable attorneys'
fees. Sublessee shall pay to Sublessor upon demand all sums paid by Sublessor
and all incidental costs and expenses of Sublessor in connection therewith,
together with interest thereon at the Late Charge as defined in the Prime Lease
from the date of the making of such expenditures.

29. SUBLESSEE'S SINGLE RIGHT OF FIRST OFFER

      (a) Sublessor shall offer to sublease to Sublessee (the "ROFO OFFER"), one
time only, on the terms set forth in this Section 29, the vacant, unfinished
space remaining on the first floor chemistry wing of the Building, as more
particularly identified on the floor plan which is attached hereto and made a
part hereof as EXHIBIT D (the "ROFO SPACE"), upon the commencement by Sublessor
of active negotiations to sublease the ROFO Space to a third party. For purposes
hereof, the term "active negotiations" shall be deemed to mean the exchange of
term sheets and/or phone calls and/or other communications with a third party
(or a broker for

                                       25
<PAGE>

such third party) regarding the leasing of the ROFO Space to such third party.
Sublessor shall provide Sublessee with written notice (the "ROFO NOTICE") of the
initiation of Sublessee's ROFO Offer.

            (i) The Base Rent payable for the ROFO Space shall be the per square
foot rental then applicable to the Unfinished Space under this Sublease.

            (ii) Sublessee's proportionate share for the ROFO Space shall be
calculated accordingly under the terms of this Sublease with respect to
obligations under Section 4 of this Sublease.

            (iii) The term of the ROFO Space shall be coterminous with the Term
of this Sublease as same may be earlier terminated.

            (iv) Sublessee shall accept the ROFO Space in its "as-is" condition
on the ROFO Space Commencement Date (as hereinafter defined), and Sublessor
shall not be required to perform any work in the ROFO Space, provide any rent
abatement or any other rent concessions, make any contributions, or render any
services to make the ROFO Space ready for Sublessee's use or occupancy.

            (v) On the ROFO Space Commencement Date, the Subleased Premises
shall be deemed to include the ROFO Space for all purposes of this Sublease and
except as set forth in this Section 29, the subleasing of the ROFO Space shall
be upon all of the other then applicable terms, covenants and conditions
contained in this Sublease with respect to the Subleased Premises.

      (b) If Sublessee chooses to accept the ROFO Offer in accordance with the
provisions of this Article, Sublessee shall notify Sublessor in writing within
seven (7) days of the date of the ROFO Notice that Sublessee will accept the
ROFO Offer. TIME SHALL BE OF THE ESSENCE with respect thereto. Sublessee agrees
that if it accepts the ROFO Offer, it shall be bound by and subject to the terms
stated therein. The ROFO Space Commencement Date shall be the date which is
seventeen (17) days after the date of the ROFO Notice.

      (c) Promptly after the acceptance of the ROFO Offer, (i) the parties shall
execute, upon the request of either party, any amendment or other documentation
reasonably requested to reflect Sublessee's acceptance of the ROFO Offer and the
inclusion of the ROFO Space within the Subleased Premises. Notwithstanding the
foregoing, Sublessee agrees that failure or omission to execute such
documentation shall not effect the inclusion of the ROFO Space within the
Subleased Premises.

      (d) If Sublessee does not timely accept or fails to timely accept the ROFO
Offer for any reason whatsoever, the ROFO Offer shall be deemed null and void
and of no force or effect, and Sublessor shall be entitled to Sublease such ROFO
Space to others at such rental and upon such terms and conditions as Sublessor
in its sole discretion may determine. Sublessee shall, within five (5) days
after Sublessor's request therefor, deliver an instrument in form reasonably

                                       26
<PAGE>

satisfactory to Sublessor confirming the aforesaid waiver of the specifically
made ROFO Offer, but no such instrument shall be necessary to make the
provisions hereof effective.

      (e)Notwithstanding anything to the contrary contained in this Section 29,
Sublessor shall not be obligated to make the ROFO Offer to Sublessee, Sublessee
shall have no right to sublease the ROFO Space, and Sublessor shall have the
right to Sublease the ROFO Space to a third party (i) if and for as long as a
default shall then exist under this Sublease beyond any applicable notice, grace
or cure periods; or (ii) if there shall have been a termination, cancellation or
surrender of this Sublease or a surrender of all or any portion of the Subleased
Premises; or (iii) if Sublessee is not fully occupying the Subleased Premises;
or (iv) once Sublessor subleases the ROFO Space to any other third party in
accordance with the provisions of this Section 29. In addition to and not in
limitation of the foregoing, if any third party desires to sublease the ROFO
Space together with any other space in the Building (whether or not such space
is contiguous), then the provisions of this Section 29 shall be deemed null,
void and of no further force or effect, Sublessor shall be under no obligation
to make the ROFO Offer to Sublessee and Sublessee shall have no right whatsoever
to sublease the ROFO Space pursuant to the terms of this Section 29 and the
provisions of this Section 29 shall be deemed automatically terminated.

      (f) Notwithstanding anything to the contrary contained herein, as of the
date which is the 2nd anniversary of the Commencement Date, the provisions of
this Section 29 shall expire and be deemed null, void and of no further force or
effect, and Sublessor shall have no obligation to make the ROFO Offer to
Sublessee and Sublessee shall have no right whatsoever to sublease the ROFO
Space pursuant to the terms of this Section 29.

      (g) Notwithstanding anything to the contrary herein, Sublessor shall have
the right to offer or sublease the ROFO Space or any portion thereof to any of
its affiliates, subsidiaries or other related entities and such offer or
sublease shall not require Sublessor to make the ROFO Offer to Sublessee and
Sublessee shall not have the right to sublease the ROFO Space in the case of
such an offer or sublease.

30. MISCELLANEOUS.

      (a) Sublessor represents that, to the best of its knowledge, the copy of
the Prime Lease attached hereto as EXHIBIT F is a true, full and complete copy
of the Prime Lease (as redacted) and that the Prime Lease is in full force and
effect.

      (b) This Sublease may be executed in multiple counterparts, and each such
counterpart shall be considered an original, but all of which together shall
constitute one and the same instrument.

                                       27
<PAGE>

31. PARKING. Sublesee shall be entitled to its proportionate share of on-site
parking in the surface parking area serving the Building for use by its
employees, customers and invitees on a non-exclusive basis pursuant to the terms
of the Prime Lease. Sublessee acknowledges that Sublessor has no repair,
maintenance or other obligations with regard to the parking area serving the
Building, but Sublessor reserves the right to close off or otherwise alter
sections of the parking area in Sublessor's reasonable discretion.

32. FOOD SERVICE. Provided Sublessee is (i) not in default under the terms of
this Sublease and (ii) occupying substantially all of the Subleased Premises as
subtenant, Sublessor shall provide reasonable, basic food service at the
Building for Sublessee's employees to purchase breakfast and lunch ("SUBLESSOR'S
FOOD SERVICE") and Sublessor, in its sole discretion, shall have the right to
(x) relocate, diminish or otherwise change the currently existing cafeteria in
the Building and or the operations thereof and/or (y) modify the food service in
any manner, from time to time, except that Sublessor will provide Sublessor's
Food Service.

33. SIGNAGE. Provided Sublessee is not in default pursuant to the terms of this
Sublease and Sublessee is occupying substantially all of the Subleased Premises,
Sublessee shall be entitled to install, at its sole expense and subject to the
approval of Landlord pursuant to the terms of the Prime Lease and the approval
of Sublessor, which may be withheld in the Sublessor's sole discretion, a sign
for the purpose of identifying Sublessee, which sign shall be no larger than 24"
x 18"and shall be located under Sublessor's existing sign on the fixed glass
panel adjacent to main the entrance door at the main lobby of the Building.
Additionally Sublessee may install signage on the main entrance door into the
Subleased Premises. This signage shall be collectively no larger than 12" x 24".
All signage shall comply with the terms of the Prime Lease and all Laws. All
signs installed by Sublessee shall be maintained by Sublessee in good condition
and Sublessee shall remove all signs at the end of the Term and repair any
damage caused by such installation, existence of removal.

34. HAZARDOUS MATERIALS; BIO-HAZARDOUS WASTE; ISRA COMPLIANCE.

      (a) In addition to the provisions of Article 12 of the Prime Lease as
incorporated herein by reference pursuant to Paragraph 11(b) of the Sublease,
Sublessee warrants, represents and covenants to Sublessor that Sublessee's use
of the Subleased Premises will at all times comply and conform to all applicable
Laws which relate to the use, transportation, storage, placement, handling,
treatment, discharge, generation, production, existence or disposal
(collectively "USE OR TREATMENT") of any waste, waste products, radioactive
waste, petroleum products, poly-chlorinated biphenyls, asbestos, hazardous
materials as defined under applicable Laws, and any substance which is regulated
by any Laws, statute, ordinance, rule or regulation, and any Bio-Hazardous Waste
(collectively "HAZARDOUS MATERIALS"). Sublessee further covenants that it will
not engage in or permit any of Sublessee's agents, employees, representatives,
contractors, invitees, vendors, licensees sub-subtenants, assignees, or
occupants of the Subleased Premises to engage in any Use or Treatment of any
Hazardous Materials and Bio-Hazardous Waste on or which affects the Office Park,
unless said Use or Treatment complies with and conforms to all Laws relating to
such Hazardous Materials, "BIO-HAZARDOUS WASTE" means any waste, substance or
material (solid, liquid or gaseous) existing, generated,

                                       28
<PAGE>

produced or resulting from any use, storage, research, production or testing of
biological agents, including without limitation, any definition thereof or
reference thereto in applicable Laws.

      (b) At Sublessee's sole liability, risk, cost, and expense, Sublessee
shall provide proper receptacles and containers for all Hazardous Materials and
Bio-Hazardous Waste and shall make such arrangements as shall be necessary,
proper, and/or required for the Use or Treatment or disposal of Sublessee's
Hazardous Material and Bio-Hazardous Waste in strict compliance with all
applicable Laws. Scheduling for the disposal of Sublessee's Hazardous Materials
and Bio-Hazardous Waste shall be reasonably coordinated with Sublessor and
Sublessee shall, upon request by Sublessor, provide Sublessor with all required
documentation evidencing Sublessee's removal and Use or Treatment of all
Hazardous Materials and Bio-Hazardous Waste in compliance with all applicable
Laws. Sublessor assumes no duty, obligation, or liability with respect to
Sublessee's Hazardous Material and Bio-Hazardous Waste and Sublessee shall
indemnify Sublessor and Prime Landlord from all liability arising out of the
existence of Hazardous Materials and Bio-Hazardous Waste which arise during
Sublessee's (or its agents, employees, representatives, contractors, invitees,
vendors, licensees sub-subtenants, assignees or occupants of the Subleased
Premises) use or occupancy of the Subleased Premises including, without
limitation, the use, existence, creation, storage, transportation, or disposal
thereof.

      (c) Promptly upon receipt of any Notice, as hereinafter defined, from any
party, Sublessee shall deliver to Sublessor a true, correct and complete copy of
any written Notice or a true, correct and complete report of any non-written
Notice. Additionally, Sublessee shall notify Sublessor immediately after having
knowledge of any Use or Treatment of Hazardous Material or Bio-Hazardous Waste,
which does not comply with or conform to all Laws relating to such Hazardous
Material or Bio-Hazardous Waste or any Spill, as hereinafter defined, of same in
or affecting the Subleased Premises. "NOTICE" shall mean any note, notice, or
report, which constitutes or alleges, or states facts which could reasonably
result in any of the following:

            (i) any suit, proceeding, investigation, order, consent order,
injunction, writ, award or action related to or affecting or indicating the Use
or Treatment of any Hazardous Material or Bio-Hazardous Waste in or affecting
the Subleased Premises;

            (ii) any spill, contamination, discharge, leakage, release or escape
of any Hazardous Material or Bio-Hazardous Waste in or affecting the Office
Park, whether sudden or gradual, accidental or anticipated, or of any other
nature (hereinafter "SPILL");

            (iii) any dispute relating to Sublessee's or any other party's Use
or Treatment of any Hazardous Material or Bio-Hazardous Waste or any Spill in or
affecting the Office Park;

            (iv) any claims by or against any insurer related to or arising out
of any Hazardous Material or Bio-Hazardous Waste or Spill in or affecting the
Office Park;

            (v) any recommendations or requirements of any governmental or
regulatory authority, insurer or board of underwriters relating to any Use or
Treatment of Hazardous Material or Bio-Hazardous Waste or a Spill in or
affecting the Office Park; or

                                       29
<PAGE>
            (vi) any legal requirement or deficiency related to the Use or
Treatment of Hazardous Material or Bio-Hazardous Waste or any Spill in or
affecting the Office Park.

      (d) In the event that Sublessee or any of Sublessee's agents, employees,
representatives, invitees, vendors, licensees, sub-subtenants, assignees or
other party or entity entering the Office Park on behalf of or at the request of
Sublessee has caused, suffered or permitted, directly or indirectly, any Spill
in or affecting the Office Park, then Sublessee shall promptly and diligently
take all of the following actions:

            (i) notify Sublessor, as provided herein;

            (ii) take all steps necessary or required by (a) the Prime Lease and
(b) the NJDEP or the appropriate governmental or regulatory agency, to clean up
such Spill and any contamination related to the Spill, all in accordance with
the requirements, rules and regulations of gay or federal environmental
department or agency having jurisdiction over the Spill;

            (iii) fully restore the Office Park to its condition prior to the
Spill subject to the requirements of the Prime Lease and any applicable Laws and
as required by the NJDEP,

            (iv) allow Sublessor or its agents and any state or federal
environmental department or agency having jurisdiction thereof to monitor and
inspect all cleanup and restoration related to such Spill; and

            (v) provided Sublessee has not purchased or fails to maintain
environmental insurance liability coverage in the amount of at least One Million
($ 1,000,000) dollars, then if any clean-up or other remedial action is required
of Sublessee under this Section 34 which would cost more than $200,000 to
comply, at the written request of Sublessor, post a bond or obtain a letter of
credit for the benefit of Sublessor (drawn upon a company or bank satisfactory
to Sublessor) or deposit an amount of money in an escrow account under
Sublessor's name upon which bond, letter of credit or escrow Sublessee may draw,
and which bond, letter of credit or escrow shall be in an amount sufficient to
meet all of Sublessee's obligations under this Section 34. Sublessor shall have
the unfettered right to draw against the bond, letter of credit or escrow in its
discretion in the event that Sublessee is unable or unwilling to meet its
obligations under this paragraph or, if Sublessee fails to post a bond or obtain
a letter of credit or deposit such cash as is required herein, then Sublessor,
at Sublessee's cost and expense, may, but shall have no obligation, do so for
the benefit of Sublessee and do those things which Sublessee is required to do
under this Section 34 and Sublessee will reimburse Sublessor for all costs
incurred within ten (10) days of demand.

      (e) Sublessee hereby agrees that it will indemnify, defend, save and hold
harmless Sublessor and Prime Landlord and each of their respective members,
partners, officers, directors, employees and mortgagees (collectively
"INDEMNIFIED PARTIES") against and from, and to reimburse the Indemnified
Parties with respect to, any and all damages, claims, liabilities, losses, costs
and expenses (including, without limitation, reasonable attorneys' fees and
expenses, court costs, administrative costs, costs of appeals and all clean up,
administrative, fines, penalties and enforcement costs of applicable
governmental agencies) which may be incurred by or asserted

                                       30
<PAGE>

against the Indemnified Parties, either directly or indirectly, by reason or
arising out of; (i) the breach of any representation or undertaking of Sublessee
under this Section 34; or (ii) the Treatment of any Hazardous Material or any
Spill caused by or related to Sublessee or any of its agents, employees,
representatives, contractors, invitees, vendors, licensees, sub-subtenants,
assignees or other party occupying the Subleased Premises or entering the Office
Park on behalf of or at the request of Sublessee; or (iii) the presence of any
Hazardous Materials in or upon the Subleased Premises which did not exist in or
upon the Subleased Premises prior to the Commencement Date of this Sublease.
Sublessee shall not be required to indemnify the Indemnified Parties for any
damages referred to herein if such damage results from the presence of any
Hazardous Materials existing in or on the Office Park or Subleased Premises
prior to the Commencement Date of this Sublease (the "PRE-EXISTING MATERIAL")
unless such damage is related to the disturbance or exacerbation of the
Pre-Existing Material or negligence or willful misconduct (which results in the
disturbance or exacerbation of the Pre-Existing Materials) by Sublessee or any
of its agents, employees, representatives, contractors, invitees, vendors,
licensees, sub-subtenants, assignees or other party occupying the Subleased
Premises or entity entering the Office Park on behalf of or at the request of
Sublessee.

      (f) Sublessor shall indemnify Sublessee and its members, partners,
officers, directors, employees against and from any and all damages, claims,
liabilities, losses, costs and expenses (including, without limitation,
reasonable attorneys' fees and expenses, court costs, administrative costs,
costs of appeals and all clean up, administrative, fines, penalties and
eaforcement costs of applicable governmental agencies) which may be incurred by
or asserted against same, either directly or indirectly, by reason of or arising
out of the Treatment of any Hazardous Material or any Spill caused by Sublessor
or any of its agents, employees, representatives, contractors, invitees, or
vendors with respect to the Subleased Premises. Sublessor shall notify Sublessee
of any Spill (of which it has received actual or constructive notice) that
adversely affects the Subleased Premises. Sublessor shall also (i) take all
steps required by the NJDEP to clean up any Spill that adversely affects
Sublessee's use of the Subleased Premises which is caused by Sublessor or any of
its agents, employees, representatives, contractors, invitees, or vendors, or
(ii) use reasonable efforts to have the Prime Landlord or any of Sublessor's
licensees, subtenants or assignees meet their obligations with respect to any
such Spill caused by such entities which adversely affects Sublessee's use of
the Subleased Premises.

      (g) The obligations of Sublessee and Sublessor under this Section 34 shall
survive any termination or satisfaction of this Sublease.

      (h) Sublessee shall comply with ISRA and all regulations promulgated
thereunder from to time and the requirements under the Prime Lease with respect
to the activities of Sublessee at the Subleased Premises including, without
limitation the closing, termination or transfer of any operation or other
activity of the Sublessee. Notwithstanding the foregoing, Sublessee shall
provide the evidence of compliance referred to in Section 12.4 of the Prime
Lease and any other ISRA requirements related to Sublessee's use of the
Subleased Premises at least six (6) months prior to Sublessee's surrender of the
Subleased Premises or any portion thereof. Sublessee hereby represents and
warrants that its NAICS No. is 541710 and that it shall

                                       31
<PAGE>

inform Sublessor of any change in its NAICS number and obtain Sublessor's and
Landlord's consent for any change in the nature of its business to be conducted
in the Subleased Premises.

      (i) Sublessee shall have no responsibility for any ancillary or reporting
costs for ISRA compliance that arise as a result of any action or inaction of
Sublessor, including by way of example but without limitation, termination of
Sublessor's operations, except for such costs for which Sublessee would
otherwise be responsible pursuant to the terms of this Sublease.

35. TEMP LAB LICENSE. Provided Sublessee is not in default under the terms of
this Sublease, Sublessor grants Sublessee a license to use the laboratory space
and access thereto consisting of 1,280 rentable square feet and as depicted on
EXHIBIT C hereto (the "TEMP LAB"), for a term which shall commence upon the
delivery of possession of the Temp Lab to Sublessee (the " TEMP LAB COMMENCEMENT
DATE") and shall end on the date which is the six month anniversary of the Temp
Lab Commencement Date, or such earlier date upon which the Term hereunder may
expire or terminate pursuant to any provision set forth herein (the "TEMP LAB
EXPIRATION DATE") Sublessor estimates that the Temp Lab Commencement Date shall
occur no later than thirty (30) days after the Commencement Date of this
Sublease. Sublessee shall be entitled to use such Temp Lab pursuant to the terms
herein as if such Temp Lab were part of the Subleased Premises, provided however
that Sublessee shall not pay any Base Rent for said license but shall pay $10.50
per rentable square foot of the Temp Lab ($13,440 per annum; $ 1,120 per month)
as additional rent herein (the "TEMP LAB OPERATING EXPENSE CHARGE") subject to
the terms (including without limitation the escalations, in Section 4(a)) of
this Sublease. Commencing on the Commencement Date (and pro-rated for any
partial month), Sublessee shall pay the Temp Lab Operating Expense Charge in
equal monthly installments in advance on the first day of each month (prorated
for any partial month) without setoff or deduction whatsoever.

      (a) Sublessee shall accept the Temp Lab in its "as-is" condition and shall
keep the Temp Lab in good order and repair as if the Temp Lab were part of the
Subleased Premises. Sublessee shall not be entitled to make any alterations or
changes to the Temp Lab. Sublessee shall be entitled to use the fixtures (the
"FIXTURES") in the Temp Lab and shall take good care of the Fixtures at
Sublessee's sole cost and expense. All damage to the Fixtures shall be promptly
repaired by Sublessee at its sole cost and expense.

      (b) The Temp Lab is subject to all the terms and conditions of this
Sublease as if it were part of the Subleased Premises (including without
limitation, Sublessee's insurance requirements pursuant to Section 13 herein),
except as otherwise expressly set forth in this Section 35. Sublessor shall have
the right to enter upon the Temp Lab at any time to inspect the same or for any
other reason.

      (c) Sublessee shall use the Temp Lab solely as a temporary, but customary
science and chemistry laboratory and in compliance with the terms of the
Sublease (including, without limitation, the terms of Section 8), the Prime
Lease, all Laws and any policies and procedures with respect to the use of the
Temp Lab promulgated by Sublessor from time to time. Any policies and procedures
promulgated by Sublessor with respect to Sublessee's use of the Temp Lab shall
be in keeping with Sublessor's then applicable policies and procedures for use
of the

                                       32
<PAGE>

Temp Lab or space similar to the Temp Lab. In no event shall the Temp Lab be
used as a vivarium. Sublessee shall also disclose to Sublessor the existence of
any toxic reagents to be brought into or used within the Temp Lab and
Sublessee's detailed safety precautions with respect to the use, storage and
handling of these reagents. In no event shall Sublessee store, use or bring or
cause to be stored, used or brought into the Temp Lab any "Scheduled" or
controlled substances.

      (d) Sublessee acknowledges and agrees that the privileges granted to
Sublessee hereunder shall merely constitute a license and shall not be deemed to
grant Sublessee a subtenancy, leasehold or other real property interest in the
Temp Lab or any portion thereof. Sublessee shall promptly vacate and remove all
its property from the Temp Lab on the Temp Lab Expiration Date (or sooner
termination of the license granted herein or this Sublease) and repair any
damage to the Temp Lab and/or the Fixtures therein so as to place the Temp Lab
and/or the fixtures therein as closely as possible, in the same condition as
existed as of the Temp Lab Commencement Date, normal wear and tear excepted
Sublessor shall have the right, in addition to all rights or remedies it may
have at law or in equity and to deny Sublessee access to the Temp Lab If
Sublessee fails to properly vacate the Temp Lab on or prior to the Temp Lab
Expiration Date.

36. DAMAGE; DESTRUCTION; CONDEMNATION.

      (a) If all or any part of the Subleased Premises or any other part of the
Building shall be damaged by fire or other casualty or be condemned or taken in
any manner for a public or quasi - public use, then (i) Sublessor shall not be
required by this Sublease to repair, restore or rebuild the same, (ii) the
parties acknowledge that Landlord shall be required to repair, restore or
rebuild the same to the extent provided in the Prime Lease, and (iii) if by
reason of any such fire or other casualty or condemnation Sublessor shall
receive an abatement of rent or additional rent relating directly to the
Subleased Premises, there shall be a corresponding abatement of Base Rent or
additional rent payable hereunder in proportion to the percentage of the
abatement of Base Rent and Additional Rent Sublessor receives under the Prime
Lease in respect of the Subleased Premises.

      (b) If the Prime Lease shall be terminated by either party thereto
pursuant to Article 11 thereof, Sublessor shall promptly deliver written notice
thereof to Sublessee and this Sublease shall terminate on and as of the same
date, without any liability of either party to the other on account thereof

      (c) If the Prime Lease shall terminate or be terminated (by either party
thereto) pursuant to Article 24 thereof, Sublessor shall promptly deliver
written notice thereof to Sublessee and this Sublease shall terminate on and as
of the same date, without liability of either party to the other on account
thereof.

      (d) Except as provided in subsection (g) hereto, this Sublease shall not
terminate by reason of any casualty or condemnation unless the Prime Lease is
terminated by Sublessor or Landlord pursuant to the terms of the Prime Lease.

                                       33
<PAGE>

      (e) If any part of the Building shall be lawfully taken by condemnation or
in any other manner for any public or quasi-public use or purpose and this
Sublease shall not terminate pursuant to Section 36(c) hereof, then

            (i) this Sublease shall continue in full force and effect except as
provided below, and

            (ii) (A) if all of the Subleased Premises shall be so taken, then
this Sublease shall terminate, without liability of either party to the other on
account thereof, and (B) if any part, but not all, of the Subleased Premises
shall be so taken then (i) on the date of such taking this Sublease shall
terminate as to such part of the Subleased Premises, without liability of either
party with respect to such part on account thereof, and (ii) from and after such
date, the rents hereunder shall be reduced pro-rata according to the rentable
area of such part of the Subleased Premises.

      (f) In no event shall Sublessee be entitled to any portion of any award in
any proceeding with respect to any taking and Sublessee hereby assigns to
Sublessor any such portion or Interest which it may have by operation of law,
except that Sublessee may make a claim with respect to the unamortized portion
of its improvements to the Unfinished Space to the appropriate condemning
authority, provided that same does not reduce any award to Sublessor or Prime
Landlord.

      (g) Notwithstanding anything to the contrary herein, but without limiting
Prime Landlord's or Sublessor's rights under the Prime Lease, if during the last
two (2) years of the Term of this Sublease, the Subleased Premises are destroyed
by fire or other casualty which venders at least 1/3 of the floor area of the
Subleased Premises untenantable or unusable for Sublessee's intended use under
this Sublease, Sublessee shall have the right to terminate this Sublease upon
written notice to Sublessor within ten (10) days after the date of such
casualty.

      (h) In case of any termination of this Sublease (in whole or in part)
pursuant to this Section 36, rents shall be adjusted as of the date of
termination, and any prepaid rents shall be refunded.

37. ADDITIONAL LAB GASES. Sublessee at its sole cost and expense, shall have the
right to install supply tanks (the "TANKS") for the distribution of carbon
dioxide (CO(2)) gas and nitrogen gas to the Lab Space, Temp Lab and Unfinished
Space. The Tanks shall be located solely within the Premises in a location to be
approved by Sublessor in it's sole discretion. The Tanks shall be connected to
the existing piping within the Premises and Sublessee shall not make any
alterations to said existing piping without Sublessor's prior consent which
shall not be unreasonably withheld. Sublessee shall make and maintain all
connections to the existing piping in compliance with all Laws. The size and use
of such Tanks shall be in compliance with all Laws and subject to the approval
of Sublessor. Sublessee shall maintain such Tanks and connections in good order
and repair to avoid any leakage or other seepage from occurring with respect to
such Tanks and shall indemnify Landlord, pursuant to the terms of Section 12
herein, for any claim, liabilities, damages, losses costs and expenses arising
from or related to Sublessee's use, maintenance, storage or other handling of
the Tanks, the gasses within them and the connections

                                       34
<PAGE>

thereto. Sublessor shall have no liability to Sublessee with respect to
Sublessee's use of the Tanks or additional lab gasses.

                            [SIGNATURE PAGE FOLLOWS]

                                       35
<PAGE>

      IN WITNESS WHEREOF, this Sublease has been executed as of the day and year
first above written.

WITNESS:                                 SUBLESSOR:

                                         PURDUE PHARMA L.P.

By: ______________________               By: /s/ Diana Lenkowsky
                                             ------------------------
                                             Name: Diana Lenkowsky
                                             Title: Vice President

WITNESS:                                 SUBLESSEE:
                                         AMICUS THERAPEUTICS, INC.

By: ______________________               By: /s/ John F. Crowley
                                             ------------------------
                                             Name: John F. Crowley
                                             Title: CEO

                                       36

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00104-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00104-of-00352.parquet"}]]